<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1354" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1354/" /><meta name="ncbi_pagename" content="McLeod Neuroacanthocytosis Syndrome - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>McLeod Neuroacanthocytosis Syndrome - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="McLeod Neuroacanthocytosis Syndrome" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2019/05/23" /><meta name="citation_author" content="Hans H Jung" /><meta name="citation_author" content="Adrian Danek" /><meta name="citation_author" content="Ruth H Walker" /><meta name="citation_author" content="Beat M Frey" /><meta name="citation_author" content="Christoph Gassner" /><meta name="citation_pmid" content="20301528" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1354/" /><meta name="citation_keywords" content="Membrane transport protein XK" /><meta name="citation_keywords" content="XK" /><meta name="citation_keywords" content="McLeod Neuroacanthocytosis Syndrome" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="McLeod Neuroacanthocytosis Syndrome" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Hans H Jung" /><meta name="DC.Contributor" content="Adrian Danek" /><meta name="DC.Contributor" content="Ruth H Walker" /><meta name="DC.Contributor" content="Beat M Frey" /><meta name="DC.Contributor" content="Christoph Gassner" /><meta name="DC.Date" content="2019/05/23" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1354/" /><meta name="description" content="McLeod neuroacanthocytosis syndrome (designated as MLS throughout this review) is a multisystem disorder with central nervous system (CNS), neuromuscular, cardiovascular, and hematologic manifestations in males. CNS manifestations are a neurodegenerative basal ganglia disease including (1) movement disorders, (2) cognitive alterations, and (3) psychiatric symptoms. Neuromuscular manifestations include a (mostly subclinical) sensorimotor axonopathy and muscle weakness or atrophy of different degrees. Cardiac manifestations include dilated cardiomyopathy, atrial fibrillation, and tachyarrhythmia. Hematologically, MLS is defined as a specific blood group phenotype (named after the first proband, Hugh McLeod) that results from absent expression of the Kx erythrocyte antigen and weakened expression of Kell blood group antigens. The hematologic manifestations are red blood cell acanthocytosis and compensated hemolysis. Allo-antibodies in the Kell and Kx blood group system can cause strong reactions to transfusions of incompatible blood and severe anemia in affected male newborns of Kell-negative mothers. Females heterozygous for XK pathogenic variants have mosaicism for the Kell and Kx blood group antigens but usually lack CNS and neuromuscular manifestations; however, some heterozygous females may develop clinical manifestations including chorea or late-onset cognitive decline." /><meta name="og:title" content="McLeod Neuroacanthocytosis Syndrome" /><meta name="og:type" content="book" /><meta name="og:description" content="McLeod neuroacanthocytosis syndrome (designated as MLS throughout this review) is a multisystem disorder with central nervous system (CNS), neuromuscular, cardiovascular, and hematologic manifestations in males. CNS manifestations are a neurodegenerative basal ganglia disease including (1) movement disorders, (2) cognitive alterations, and (3) psychiatric symptoms. Neuromuscular manifestations include a (mostly subclinical) sensorimotor axonopathy and muscle weakness or atrophy of different degrees. Cardiac manifestations include dilated cardiomyopathy, atrial fibrillation, and tachyarrhythmia. Hematologically, MLS is defined as a specific blood group phenotype (named after the first proband, Hugh McLeod) that results from absent expression of the Kx erythrocyte antigen and weakened expression of Kell blood group antigens. The hematologic manifestations are red blood cell acanthocytosis and compensated hemolysis. Allo-antibodies in the Kell and Kx blood group system can cause strong reactions to transfusions of incompatible blood and severe anemia in affected male newborns of Kell-negative mothers. Females heterozygous for XK pathogenic variants have mosaicism for the Kell and Kx blood group antigens but usually lack CNS and neuromuscular manifestations; however, some heterozygous females may develop clinical manifestations including chorea or late-onset cognitive decline." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1354/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/mcleod/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1354/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8D2CC9E03FE721000000000B0003B6.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1354_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1354_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/mkks/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/mcad/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1354_"><span class="title" itemprop="name">McLeod Neuroacanthocytosis Syndrome</span></h1><p class="contrib-group"><span itemprop="author">Hans H Jung</span>, MD, <span itemprop="author">Adrian Danek</span>, MD, <span itemprop="author">Ruth H Walker</span>, MD,ChB, PhD, <span itemprop="author">Beat M Frey</span>, MD, and <span itemprop="author">Christoph Gassner</span>, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1354_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1354_ai__"><div class="contrib half_rhythm"><span itemprop="author">Hans H Jung</span>, MD<div class="affiliation small">Department of Neurology<br />University Hospital Zurich<br />Zurich, Switzerland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="hc.zsu@gnuj.snah" class="oemail">hc.zsu@gnuj.snah</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Adrian Danek</span>, MD<div class="affiliation small">Neurologische Klinik<br />Ludwig-Maximilians-Universit&#x000e4;t<br />M&#x000fc;nchen, Germany<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ed.uml@kenad" class="oemail">ed.uml@kenad</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Ruth H Walker</span>, MD,ChB, PhD<div class="affiliation small">Department of Neurology<br />Veterans Affairs Medical Center<br />Bronx, New York<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.mssm@reklaw.htur" class="oemail">ude.mssm@reklaw.htur</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Beat M Frey</span>, MD<div class="affiliation small">Blood Transfusion Service<br />Swiss Red Cross<br />Schlieren/Z&#x000fc;rich, Switzerland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="hc.dsbhz@yerf.mb" class="oemail">hc.dsbhz@yerf.mb</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Christoph Gassner</span>, PhD<div class="affiliation small">Blood Transfusion Service<br />Swiss Red Cross<br />Schlieren/Z&#x000fc;rich, Switzerland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="hc.dsbhz@renssag.c" class="oemail">hc.dsbhz@renssag.c</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">December 3, 2004</span>; Last Update: <span itemprop="dateModified">May 23, 2019</span>.</p><p><em>Estimated reading time: 30 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="mcleod.Summary" itemprop="description"><h2 id="_mcleod_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>McLeod neuroacanthocytosis syndrome (designated as MLS throughout this review) is a multisystem disorder with central nervous system (CNS), neuromuscular, cardiovascular, and hematologic manifestations in males. CNS manifestations are a neurodegenerative basal ganglia disease including (1) movement disorders, (2) cognitive alterations, and (3) psychiatric symptoms. Neuromuscular manifestations include a (mostly subclinical) sensorimotor axonopathy and muscle weakness or atrophy of different degrees. Cardiac manifestations include dilated cardiomyopathy, atrial fibrillation, and tachyarrhythmia. Hematologically, MLS is defined as a specific blood group <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> (named after the first <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>, Hugh McLeod) that results from absent expression of the Kx erythrocyte antigen and weakened expression of Kell blood group antigens. The hematologic manifestations are red blood cell acanthocytosis and compensated hemolysis. Allo-antibodies in the Kell and Kx blood group system can cause strong reactions to transfusions of incompatible blood and severe anemia in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male newborns of Kell-negative mothers. Females <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for <i>XK</i> pathogenic variants have <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> for the Kell and Kx blood group antigens but usually lack CNS and neuromuscular manifestations; however, some heterozygous females may develop clinical manifestations including chorea or late-onset cognitive decline.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of MLS is established in a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with suggestive clinical, laboratory, and neuroimaging studies; a family history consistent with <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> inheritance; and identification on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of either a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <i>XK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (90% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males) or a hemizygous <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of Xp21.1 involving <i>XK</i> (10% of affected males).</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations</i>: Dopamine antagonists (e.g., tiapride, clozapine, quetiapine) and the dopamine depletory (tetrabenazine) to ameliorate chorea; treatment of psychiatric problems, cardiac abnormalities, and seizures is based on the clinical findings; long-term and continuous multidisciplinary psychosocial support is needed for <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals and their families.</p><p><i>Agents/circumstances to avoid:</i> Blood transfusions with Kx antigens should be avoided in males with MLS. Kx-negative blood or, if possible, banked autologous blood should be used.</p><p><i>Evaluation of relatives at risk</i>: It is appropriate to clarify the genetic status of apparently asymptomatic at-risk relatives of any age in order to identify as early as possible those who would benefit from: (1) detailed blood compatibility information to prevent transfusion of Kx+ homologous blood products, and (2) possible prophylactic cryopreservation of autologous blood for use in future transfusions.</p><p><i>Surveillance</i>: Holter ECG and echocardiography every two to three years in those without known cardiac complications; consider placement of prophylactic cardiac pacemaker; monitor for seizures; monitor serum CK concentrations for evidence of rhabdomyolysis if excessive movement disorders are present or if neuroleptic medications are being used.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>MLS is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner. If the mother of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a>, the chance of transmitting the <i>XK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in each pregnancy is 50%. Males who inherit the <i>XK</i> variant will be affected; females who inherit the <i>XK</i> variant will be heterozygous and will usually not be affected. Affected males pass the <i>XK</i> pathogenic variant to all of their daughters and none of their sons. Once the <i>XK</i> pathogenic variant has been identified in an affected family member, <a class="def" href="/books/n/gene/glossary/def-item/carrier-testing/">carrier testing</a> for at-risk females, prenatal testing for a pregnancy at increased risk, and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p></div></div><div id="mcleod.Diagnosis"><h2 id="_mcleod_Diagnosis_">Diagnosis</h2><div id="mcleod.Suggestive_Findings"><h3>Suggestive Findings</h3><p>The diagnosis of McLeod neuroacanthocytosis syndrome (MLS) <b>should be suspected/considered</b> in an individual with the following clinical and laboratory findings and family history.</p><div id="mcleod.Clinical_Findings"><h4>Clinical Findings</h4><p><b>CNS manifestations</b></p><ul><li class="half_rhythm"><div>Progressive chorea syndrome similar to that seen in Huntington disease including the clinical triad of movement disorder, cognitive alterations, and psychiatric manifestations</div></li><li class="half_rhythm"><div>Seizures, mostly generalized</div></li></ul><p><b>Neuromuscular manifestations (often subclinical or mild)</b></p><ul><li class="half_rhythm"><div>Sensorimotor axonopathy</div></li><li class="half_rhythm"><div>Neurogenic muscle atrophy, including unexplained elevation of creatine phosphokinase</div></li><li class="half_rhythm"><div>Myopathy</div></li></ul><p><b>Cardiomyopathy</b></p><ul><li class="half_rhythm"><div>Echocardiography may demonstrate congestive cardiomyopathy or dilated cardiomyopathy [<a class="bk_pop" href="#mcleod.REF.mohiddin.2004">Mohiddin &#x00026; Fananapazzir 2004</a>].</div></li><li class="half_rhythm"><div>Electrocardiography (ECG) may demonstrate atrial fibrillation or tachyarrhythmia [<a class="bk_pop" href="#mcleod.REF.mohiddin.2004">Mohiddin &#x00026; Fananapazzir 2004</a>].</div></li></ul><p><b>Family history</b> consistent with <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> inheritance</p></div><div id="mcleod.LaboratoryElectrophysiologic_Find"><h4>Laboratory/Electrophysiologic Findings</h4><p><b>McLeod blood group <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a></b></p><ul><li class="half_rhythm"><div class="half_rhythm"><b>In <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males</b> the diagnosis of the McLeod blood group <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is based on the immunohematologic determination of absent expression of the Kx erythrocyte antigen and reduced expression of the Kell blood group antigens using human anti-Kx and monoclonal anti-Kell antibodies, respectively [<a class="bk_pop" href="#mcleod.REF.jung.2007.112">Jung et al 2007</a>, <a class="bk_pop" href="#mcleod.REF.roulis.2018.1554">Roulis et al 2018</a>]. Serologically absent Kx erythrocyte antigen and serologically weakened or absent Kell antigens are pathognomonic for the McLeod blood group phenotype.</div><div class="half_rhythm">McLeod blood group <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is established by showing negativity for Kx erythrocyte antigen and weakened or absent expression of Kell antigens, thus differentiating the phenotype from individuals with <i>KEL</i>-null (K<sub>0</sub>) phenotype, which is characterized by strong expression of Kx. Expression of Kx / Kell protein complex on red blood cell membrane can also be evaluated by flow cytometry.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>In <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females</b> mixed red blood cell populations may be identified with flow cytometric analysis of Kx and Kell RBC antigens on red blood cell membrane [<a class="bk_pop" href="#mcleod.REF.jung.2007.112">Jung et al 2007</a>, <a class="bk_pop" href="#mcleod.REF.roulis.2018.1554">Roulis et al 2018</a>].</div></li></ul><p><b>Red blood cell studies</b></p><ul><li class="half_rhythm"><div class="half_rhythm"><b>RBC acanthocytosis</b> is found in virtually all males with MLS. Accurate determination of RBC acanthocytosis is challenging. The best procedure requires diluting whole blood samples 1:1 with heparinized saline followed by incubation for 60 minutes at room temperature; wet cell monolayers are then prepared for phase-contrast microscopy. When all RBCs with spicules (corresponding to type AI/AII acanthocytes and echinocytes) are counted, normal controls show less than 6.3% acanthocytes/echinocytes [<a class="bk_pop" href="#mcleod.REF.storch.2005.84">Storch et al 2005</a>]. Acanthocyte count in MLS may vary considerably but usually ranges between 8% and 30%. Repeat testing may be required, as the findings of acanthocyte determinations may fluctuate over time. Proven presence of acanthocytes, however, is not a necessary precondition to make the diagnosis of the McLeod neuroacanthocytosis syndrome. Note: No data regarding the age at which acanthocytosis develops are available.</div><div class="half_rhythm">Confirmation of erythrocyte morphology by scanning electron microscopy (if available) may be helpful.</div></li></ul><p><b>Compensated hemolysis</b> (i.e., hemolysis without anemia) is found in virtually all males with MLS. The following can be used to evaluate for hemolysis:</p><ul><li class="half_rhythm"><div>Assessment for allo-antibodies against high-frequency antigens (anti-public antibodies) such as anti-Kx, anti-K20, and anti-Km antibodies. While these anti-public antibodies do not contribute to the auto-hemolysis in MLS, they need to be considered in homologous transfusion.</div></li><li class="half_rhythm"><div>Exclusion of autoimmune hemolytic anemia by negative direct antiglobulin test</div></li><li class="half_rhythm"><div>Investigation for biochemical markers of hemolysis (LDH, haptoglobin, bilirubin, reticulocytes) and muscle disorder (CPK, CPK-MB)</div></li></ul><p><b>Neuromuscular studies</b></p><ul><li class="half_rhythm"><div><b>Muscle enzymes.</b> All males with MLS examined to date have had elevated serum creatine phosphokinase (CK) concentrations reaching values up to 4,000 U/L [<a class="bk_pop" href="#mcleod.REF.danek.2001a.755">Danek et al 2001a</a>, <a class="bk_pop" href="#mcleod.REF.jung.2001a.384">Jung et al 2001a</a>].</div></li><li class="half_rhythm"><div><b>Electromyography</b> may demonstrate neurogenic and myopathic changes [<a class="bk_pop" href="#mcleod.REF.danek.2001a.755">Danek et al 2001a</a>].</div></li><li class="half_rhythm"><div><b>Nerve conduction studies</b> may demonstrate axonal damage of variable degree [<a class="bk_pop" href="#mcleod.REF.danek.2001a.755">Danek et al 2001a</a>].</div></li><li class="half_rhythm"><div><b>Muscle computed tomography (CT)</b> may reveal a selective pattern of fatty degeneration of lower-leg muscles preferentially affecting the vastus lateralis, biceps femoris, and adductor magnus muscles, and sparing the gracilis, semitendinosus, and lateral head of the gastrocnemius muscle [<a class="bk_pop" href="#mcleod.REF.ishikawa.2000.1113">Ishikawa et al 2000</a>].</div></li></ul></div><div id="mcleod.Central_Nervous_System_Studies"><h4>Central Nervous System Studies</h4><p><b>Neuroimaging</b></p><ul><li class="half_rhythm"><div>In <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males, CT and magnetic resonance imaging (MRI) of the brain may demonstrate atrophy of the caudate nucleus and putamen of variable degree [<a class="bk_pop" href="#mcleod.REF.danek.2001a.755">Danek et al 2001a</a>, <a class="bk_pop" href="#mcleod.REF.jung.2001a.384">Jung et al 2001a</a>]. Basal ganglia volumes are inversely correlated with disease duration [<a class="bk_pop" href="#mcleod.REF.jung.2001a.384">Jung et al 2001a</a>]. A follow-up study of three individuals with MLS over seven years using an automated subcortical segmentation procedure demonstrated decreasing caudate volumes [<a class="bk_pop" href="#mcleod.REF.valko.2010.612">Valko et al 2010</a>].</div></li><li class="half_rhythm"><div>In two males with MLS, brain MRI demonstrated extended T<sub>2</sub>-weighted hyperintense white matter alterations [<a class="bk_pop" href="#mcleod.REF.danek.2001a.755">Danek et al 2001a</a>, <a class="bk_pop" href="#mcleod.REF.nicholl.2004.1200">Nicholl et al 2004</a>].</div></li><li class="half_rhythm"><div>In asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females, and early in the disease course in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males, neuroimaging findings may be normal [<a class="bk_pop" href="#mcleod.REF.jung.2001a.384">Jung et al 2001a</a>, <a class="bk_pop" href="#mcleod.REF.jung.2003.928">Jung et al 2003</a>].</div></li></ul></div></div><div id="mcleod.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p><b>Male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The diagnosis of McLeod neuroacanthocytosis syndrome <b>is established</b> in a male proband with suggestive clinical and laboratory findings, neuroimaging studies, and family history, as well as <b>one of the following</b> identified on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1354/table/mcleod.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="figmcleodTmoleculargenetictestingused" rid-ob="figobmcleodTmoleculargenetictestingused">Table 1</a>):</p><ul><li class="half_rhythm"><div class="half_rhythm">A <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> involving <i>XK</i> (~90% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals) [<a class="bk_pop" href="#mcleod.REF.dotti.2000.1282">Dotti et al 2000</a>, <a class="bk_pop" href="#mcleod.REF.danek.2001a.755">Danek et al 2001a</a>, <a class="bk_pop" href="#mcleod.REF.jung.2001b.1346">Jung et al 2001b</a>, <a class="bk_pop" href="#mcleod.REF.jung.2003.928">Jung et al 2003</a>]</div></li><li class="half_rhythm"><div class="half_rhythm">A <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of Xp21.1 involving <i>XK</i> (10% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals) [<a class="bk_pop" href="#mcleod.REF.kawakami.1999.36">Kawakami et al 1999</a>, <a class="bk_pop" href="#mcleod.REF.el_nemer.2000.29">El Nemer et al 2000</a>, <a class="bk_pop" href="#mcleod.REF.danek.2001a.755">Danek et al 2001a</a>, <a class="bk_pop" href="#mcleod.REF.wendel.2004.1579">Wendel et al 2004</a>]</div><div class="half_rhythm">Note: Deletions involving <i>XK</i> vary in size from intragenic to larger multigene deletions. Failure to generate <i>XK</i> sequence in a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is consistent with a <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>; however, other techniques are needed to define the breakpoints of the deletion (see <a class="figpopup" href="/books/NBK1354/table/mcleod.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="figmcleodTmoleculargenetictestingused" rid-ob="figobmcleodTmoleculargenetictestingused">Table 1</a>).</div></li></ul><p><b>Female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The diagnosis of McLeod neuroacanthocytosis syndrome <b>is usually established</b> in a female proband with one of the following: (1) detection by flow cytometry of two populations of RBC, one with normal expression of Kell antigens and one with reduced expression, or (2) detection of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in XK by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p><p>Note: Based on published cases, <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females do not have RBC acanthocytosis or elevated CK serum levels.</p><p>Molecular genetic testing approaches can include a combination of <b><a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted testing</b> (single-gene testing, <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a>) and <b>comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (<a class="def" href="/books/n/gene/glossary/def-item/chromosomal-microarray/">chromosomal microarray</a> analysis, <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a>, <a class="def" href="/books/n/gene/glossary/def-item/exome-array/">exome array</a>, <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>). Gene-targeted testing requires that the clinician determine which gene(s) are likely involved, whereas genomic testing does not.</p><p>There are three options for establishing the diagnosis of McLeod neuroacanthocytosis syndrome:</p><ul><li class="half_rhythm"><div><a href="#mcleod.Option_1"><b>Option 1.</b></a> Determination of the McLeod blood group <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> followed by CMA for individuals with findings suggestive of a contiguous-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a></div></li><li class="half_rhythm"><div><a href="#mcleod.Option_2"><b>Option 2.</b></a> Determination of the McLeod blood group <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> followed by single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing for those in whom McLeod blood group phenotyping supports the diagnosis</div></li><li class="half_rhythm"><div><a href="#mcleod.Option_3"><b>Option 3.</b></a> Multigene panel or comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing for symptomatic individuals in whom the diagnosis of McLeod neuroacanthocytosis syndrome has not been considered</div></li></ul><div id="mcleod.Option_1"><h4>Option 1</h4><p>(Determination of the McLeod blood group <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> followed by CMA for individuals with findings suggestive of a contiguous-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>)</p><p><b>Chromosomal microarray analysis (CMA).</b> For individuals with suggestive clinical features of McLeod neuroacanthocytosis syndrome and one or more of the disorders observed in contiguous-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions that include <i>XK</i>, CMA should be performed first to detect large deletions that cannot be detected by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> or gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>. These other disorders and their causative genes include Duchenne muscular dystrophy (<i>DMD</i>), <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> chronic granulomatous disease (<i>CYBB</i>), X-linked retinitis pigmentosa (<i>RPGR</i>), and ornithine transcarbamylase deficiency (<i>OTC</i>). See <a href="#mcleod.Genetically_Related_Allelic_Disor">Genetically Related Disorders</a>, <b>Contiguous-gene rearrangements</b>.</p><p>Note: Alternatively, <a class="def" href="/books/n/gene/glossary/def-item/next-generation-sequencing/">next-generation sequencing</a> (NGS), such as <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> or <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>, may identify a large <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> involving <i>XK</i>, particularly in a male; however, detection of a deletion by NGS must be confirmed by an orthogonal (i.e., statistically independent) method.</p></div><div id="mcleod.Option_2"><h4>Option 2</h4><p>(Determination of the McLeod blood group <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> followed by single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing for those in whom McLeod blood group phenotyping supports the diagnosis)</p><p><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> When the phenotypic and laboratory findings (specifically McLeod blood group phenotyping) support the diagnosis of McLeod neuroacanthocytosis syndrome [<a class="bk_pop" href="#mcleod.REF.frey.2015.277">Frey et al 2015</a>], perform <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of <i>XK</i> to detect small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants. If no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found, perform gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> to detect intragenic deletions or duplications.</p><p>Note: (1) Lack of amplification by <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> prior to <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> can suggest a putative (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> on the X <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males; confirmation requires additional testing by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>. (2) Gene-targeted deletion/duplication testing will detect deletions ranging from a single exon to the whole gene; however, breakpoints of large deletions and/or deletion of adjacent genes may not be detected in an affected female by these methods and may require CMA (see <a href="#mcleod.Option_1">Option 1</a>).</p></div><div id="mcleod.Option_3"><h4>Option 3</h4><p>(For symptomatic individuals in whom the diagnosis of McLeod neuroacanthocytosis syndrome has not been considered)</p><p>When the diagnosis of McLeod neuroacanthocytosis syndrome has not been considered in a symptomatic individual, the options are a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> or comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing.</p><p><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>XK</i> and other genes of interest (see <a href="#mcleod.Differential_Diagnosis">Differential Diagnosis</a>) is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests. For this disorder a multigene panel that also includes deletion/duplication analysis is recommended (see <a class="figpopup" href="/books/NBK1354/table/mcleod.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="figmcleodTmoleculargenetictestingused" rid-ob="figobmcleodTmoleculargenetictestingused">Table 1</a>).</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p><p><b>Comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> involves either e<b>xome sequencing</b> or <b><a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a></b>. If <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> is not diagnostic, <a class="def" href="/books/n/gene/glossary/def-item/exome-array/">exome array</a> (when clinically available) needs be considered to detect (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications that cannot be detected by exome sequencing.</p><p>For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div id="mcleod.T.molecular_genetic_testing_used" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in McLeod Neuroacanthocytosis Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1354/table/mcleod.T.molecular_genetic_testing_used/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mcleod.T.molecular_genetic_testing_used_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_mcleod.T.molecular_genetic_testing_used_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_mcleod.T.molecular_genetic_testing_used_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_mcleod.T.molecular_genetic_testing_used_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_mcleod.T.molecular_genetic_testing_used_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>XK</i></td><td headers="hd_h_mcleod.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3,&#x000a0;4</sup></td><td headers="hd_h_mcleod.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~60%&#x000a0;<sup>5,&#x000a0;6</sup></td></tr><tr><td headers="hd_h_mcleod.T.molecular_genetic_testing_used_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>7</sup></td><td headers="hd_h_mcleod.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~40%&#x000a0;<sup>5,&#x000a0;6,&#x000a0;8</sup></td></tr><tr><td headers="hd_h_mcleod.T.molecular_genetic_testing_used_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Chromosomal microarray analysis&#x000a0;<sup>9</sup></td><td headers="hd_h_mcleod.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~30%&#x000a0;<sup>6,&#x000a0;8</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="mcleod.TF.1.1"><p class="no_margin">See <a href="/books/NBK1354/#mcleod.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="mcleod.TF.1.2"><p class="no_margin">See <a href="#mcleod.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="mcleod.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="mcleod.TF.1.4"><p class="no_margin">Lack of amplification by <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> prior to <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> can suggest a putative (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> on the X <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males; confirmation requires additional testing by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>.</p></div></dd><dt>5. </dt><dd><div id="mcleod.TF.1.5"><p class="no_margin"><a class="bk_pop" href="#mcleod.REF.roulis.2018.1554">Roulis et al [2018]</a></p></div></dd><dt>6. </dt><dd><div id="mcleod.TF.1.6"><p class="no_margin">A current list of XK pathogenic variants is maintained here: <a href="http://www.isbtweb.org/working-parties/red-cell-immunogenetics-and-blood-group-terminology/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">IBST</a> (scroll down; select <b>Blood Group Allele Terminology</b>, then <b>XK</b>).</p></div></dd><dt>7. </dt><dd><div id="mcleod.TF.1.7"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications. Gene-targeted deletion/duplication testing will detect deletions ranging from a single exon to the whole gene; however, breakpoints of large deletions and/or deletion of adjacent genes (see <a href="#mcleod.Genetically_Related_Allelic_Disor">Genetically Related Disorders</a>, <b>Contiguous-gene rearrangements</b>) may not be detected by these methods.</p></div></dd><dt>8. </dt><dd><div id="mcleod.TF.1.8"><p class="no_margin">Note that most reported deletions and duplications are large enough to likely be detected by CMA; however, <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> does have a higher resolution.</p></div></dd><dt>9. </dt><dd><div id="mcleod.TF.1.9"><p class="no_margin">Chromosomal microarray analysis (CMA) uses oligonucleotide or SNP arrays to detect genome-wide large deletions/duplications (including <i>XK</i>) that cannot be detected by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>. The ability to determine the size of the <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> depends on the type of microarray used and the density of probes in the Xp21.1 region. CMA designs in current clinical use target the Xp21.1 region.</p></div></dd></dl></div></div></div></div></div></div><div id="mcleod.Clinical_Characteristics"><h2 id="_mcleod_Clinical_Characteristics_">Clinical Characteristics</h2><div id="mcleod.Clinical_Description"><h3>Clinical Description</h3><p>McLeod neuroacanthocytosis syndrome (MLS) is a multisystem disorder with central nervous system (CNS), neuromuscular, and hematologic manifestations in males. CNS manifestations of MLS resemble <a href="/books/n/gene/huntington/">Huntington disease</a>. Symptoms comprise the prototypic triad of a progressive neurodegenerative basal ganglia disease including (1) movement disorder, (2) cognitive alterations, and (3) psychiatric symptoms [<a class="bk_pop" href="#mcleod.REF.danek.2001a.755">Danek et al 2001a</a>, <a class="bk_pop" href="#mcleod.REF.jung.2007.112">Jung et al 2007</a>]. It should be noted that each sign and symptom may develop in isolation or in variable combinations.</p><p>Choreiform movements are the presenting manifestation in about 30% of individuals with MLS, and develop in up to 95% of individuals over time [<a class="bk_pop" href="#mcleod.REF.danek.2001b.882">Danek et al 2001b</a>, <a class="bk_pop" href="#mcleod.REF.jung.2001a.384">Jung et al 2001a</a>, <a class="bk_pop" href="#mcleod.REF.hewer.2007.3285">Hewer et al 2007</a>]. Some individuals with MLS develop head drops, feeding dystonia, and gait abnormalities, manifestations formerly believed to be specific to another type of neuroacanthocytosis, the <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> <a href="/books/n/gene/chac/">chorea-acanthocytosis</a> [<a class="bk_pop" href="#mcleod.REF.chauveau.2011.1562">Chauveau et al 2011</a>, <a class="bk_pop" href="#mcleod.REF.gantenbein.2011.2123">Gantenbein et al 2011</a>].</p><p>Cognitive alterations are not a major presenting feature of MLS; however, frontal-type cognitive deficits are eventually found in at least 50% of individuals during the course of the disease [<a class="bk_pop" href="#mcleod.REF.danek.2001a.755">Danek et al 2001a</a>, <a class="bk_pop" href="#mcleod.REF.jung.2001a.384">Jung et al 2001a</a>, <a class="bk_pop" href="#mcleod.REF.danek.2004">Danek et al 2004</a>, <a class="bk_pop" href="#mcleod.REF.hewer.2007.3285">Hewer et al 2007</a>].</p><p>About 20% of individuals initially manifest psychiatric abnormalities including personality disorder, anxiety, depression, obsessive-compulsive disorder, bipolar disorder, or schizo-affective disorder. Psychopathology develops in about 80% of individuals over time [<a class="bk_pop" href="#mcleod.REF.danek.2001a.755">Danek et al 2001a</a>, <a class="bk_pop" href="#mcleod.REF.jung.2001a.384">Jung et al 2001a</a>, <a class="bk_pop" href="#mcleod.REF.jung.2004.722">Jung &#x00026; Haker 2004</a>, <a class="bk_pop" href="#mcleod.REF.walterfang.2011.1275">Walterfang et al 2011</a>].</p><p>Seizures are the presenting manifestation in about 20% of individuals. Up to 40% of individuals with MLS eventually have seizures, usually described as generalized seizures.</p><p>Neuromuscular manifestations are not a common presenting manifestation of MLS. However, almost all individuals with MLS have absent deep tendon reflexes as an indication of a (mostly subclinical) sensorimotor axonopathy [<a class="bk_pop" href="#mcleod.REF.danek.2001a.755">Danek et al 2001a</a>, <a class="bk_pop" href="#mcleod.REF.jung.2001a.384">Jung et al 2001a</a>]. About 50% of individuals develop clinically relevant muscle weakness or atrophy of a neurogenic nature during the disease course. Deterioration rate is slow, and few individuals develop severe weakness [<a class="bk_pop" href="#mcleod.REF.kawakami.1999.36">Kawakami et al 1999</a>, <a class="bk_pop" href="#mcleod.REF.danek.2001a.755">Danek et al 2001a</a>, <a class="bk_pop" href="#mcleod.REF.jung.2001a.384">Jung et al 2001a</a>, <a class="bk_pop" href="#mcleod.REF.hewer.2007.3285">Hewer et al 2007</a>].</p><p>Cardiac manifestations including dilated cardiomyopathy, atrial fibrillation, and tachyarrhythmia are rarely presenting signs and symptoms of MLS. About 60% of individuals develop cardiac manifestations over time [<a class="bk_pop" href="#mcleod.REF.witt.1992.302">Witt et al 1992</a>, <a class="bk_pop" href="#mcleod.REF.danek.2001a.755">Danek et al 2001a</a>, <a class="bk_pop" href="#mcleod.REF.oechslin.2009.130">Oechslin et al 2009</a>]. In seven males with MLS, one presented with a cardiomyopathy and died from sudden cardiac death in the absence of any cardiovascular risk factors. Autopsy demonstrated eccentric hypertrophy and mild left ventricular dilatation. Histopathology was not specific and revealed focal myocyte hypertrophy, slight variation of myofiber size, and patchy interstitial fibrosis [<a class="bk_pop" href="#mcleod.REF.witt.1992.302">Witt et al 1992</a>, <a class="bk_pop" href="#mcleod.REF.oechslin.2009.130">Oechslin et al 2009</a>]. Comparable histologic findings were observed in the heart of the only individual with MLS who has undergone cardiac transplantation [<a class="bk_pop" href="#mcleod.REF.laurencin.2018.64">Laurencin et al 2018</a>].</p><p>Hepatosplenomegaly, most probably resulting from compensated hemolysis, occurs in about one third of males with MLS [<a class="bk_pop" href="#mcleod.REF.danek.2001a.755">Danek et al 2001a</a>].</p><p>About 30% of males with the McLeod blood group <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> do not have neuromuscular or CNS findings at the time of initial diagnosis of the blood group abnormalities and are only recognized during routine workup in blood banks or in the course of family evaluations [<a class="bk_pop" href="#mcleod.REF.danek.2001a.755">Danek et al 2001a</a>, <a class="bk_pop" href="#mcleod.REF.jung.2001a.384">Jung et al 2001a</a>, <a class="bk_pop" href="#mcleod.REF.jung.2007.112">Jung et al 2007</a>]. However, most males with the McLeod blood group phenotype developed neurologic manifestations during long-term follow up [<a class="bk_pop" href="#mcleod.REF.danek.2001a.755">Danek et al 2001a</a>, <a class="bk_pop" href="#mcleod.REF.hewer.2007.3285">Hewer et al 2007</a>].</p><p>The age of onset of neurologic manifestations ranges from 18 to 61 years; the majority of individuals become symptomatic before age 40 years. Almost all clinical observations indicate a slowly progressive disease course [<a class="bk_pop" href="#mcleod.REF.danek.2001a.755">Danek et al 2001a</a>, <a class="bk_pop" href="#mcleod.REF.jung.2001a.384">Jung et al 2001a</a>, <a class="bk_pop" href="#mcleod.REF.valko.2010.612">Valko et al 2010</a>]. Because of difficulty in determining the exact onset of disease, few reliable data regarding disease duration are available. Activities of daily living may become impaired as a result of the movement disorder, psychiatric manifestations, intellectual disability, and/or cardiomyopathy.</p><p>The interval between reported disease onset and death ranges from seven to 51 years, and the mean age of death is 53 years (range: 31 to 69 years) [<a class="bk_pop" href="#mcleod.REF.danek.2001a.755">Danek et al 2001a</a>, <a class="bk_pop" href="#mcleod.REF.jung.2001a.384">Jung et al 2001a</a>, <a class="bk_pop" href="#mcleod.REF.hewer.2007.3285">Hewer et al 2007</a>, <a class="bk_pop" href="#mcleod.REF.walker.2019.158">Walker et al 2019</a>]. Mean disease duration from diagnosis to death was 21 years [<a class="bk_pop" href="#mcleod.REF.walker.2019.158">Walker et al 2019</a>]. Cardiac problems, in particular tachyarrhythmia, appear to be a major cause of premature death in MLS; other causes of death included pneumonia, seizure, suicide, and sepsis [<a class="bk_pop" href="#mcleod.REF.walker.2019.158">Walker et al 2019</a>].</p><p>The hematologic manifestations are red blood cell acanthocytosis and compensated hemolysis. Allo-antibodies in the Kell and Kx blood group system can cause strong reactions to transfusions of incompatible blood and severe anemia in newborns of Kell-negative mothers.</p><div id="mcleod.Females"><h4>Females</h4><p>Females who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <i>XK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> for the Kell system blood group and RBC acanthocytosis by virtue of <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a> [<a class="bk_pop" href="#mcleod.REF._yen.1996.160">&#x000d8;yen et al 1996</a>, <a class="bk_pop" href="#mcleod.REF.kawakami.1999.36">Kawakami et al 1999</a>, <a class="bk_pop" href="#mcleod.REF.jung.2001a.384">Jung et al 2001a</a>, <a class="bk_pop" href="#mcleod.REF.singleton.2003.682">Singleton et al 2003</a>, <a class="bk_pop" href="#mcleod.REF.jung.2007.112">Jung et al 2007</a>]. Some heterozygous females may develop clinical manifestations such as chorea or late-onset cognitive decline.</p><p>The most probable reason for the following clinical manifestations observed in female heterozygotes is skewed <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a>, in which the X chromosome with the normal <i>XK</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is by chance inactivated in a disproportionately large number of cells [<a class="bk_pop" href="#mcleod.REF.ho.1996.672">Ho et al 1996</a>]. Pertinent observations are:</p><ul><li class="half_rhythm"><div>One female <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> developed the typical MLS <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#mcleod.REF.hardie.1991.13">Hardie et al 1991</a>].</div></li><li class="half_rhythm"><div>A female <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> had acanthocytosis, a bimodal pattern of Kell blood group antigens on flow cytometry, elevated serum creatine kinase concentrations, and a tic-like movement disorder [<a class="bk_pop" href="#mcleod.REF.kawakami.1999.36">Kawakami et al 1999</a>].</div></li><li class="half_rhythm"><div>In one family, female heterozygotes had slight cognitive deficits and reduced striatal glucose uptake in the absence of an obvious movement disorder [<a class="bk_pop" href="#mcleod.REF.jung.2001a.384">Jung et al 2001a</a>].</div></li></ul></div><div id="mcleod.Other_Studies"><h4>Other Studies</h4><p><b>Serum concentrations of LDH, AST, and ALT</b> may also be elevated [<a class="bk_pop" href="#mcleod.REF.danek.2001a.755">Danek et al 2001a</a>, <a class="bk_pop" href="#mcleod.REF.jung.2001a.384">Jung et al 2001a</a>]. These elevated values reflect muscle cell pathology and should not be misinterpreted as hepatic pathology.</p><p><b>Magnetic resonance spectroscopy (MRS).</b>
<sup>1</sup>H-MRS demonstrates pathologic NAA/(Cr+Cho) ratios in frontal, temporal, and insular areas with an individual pattern in males with MLS who have predominant psychiatric or neuropsychological manifestations [<a class="bk_pop" href="#mcleod.REF.dydak.2006.17">Dydak et al 2006</a>].</p><p><b>Nuclear medicine.</b> SPECT studies using <sup>123</sup>I-IMP and <sup>123</sup>I-IBZM revealed reduction of striatal perfusion and striatal D2-receptor density, respectively, in some males with MLS [<a class="bk_pop" href="#mcleod.REF.danek.1994.117">Danek et al 1994</a>, <a class="bk_pop" href="#mcleod.REF.oechsner.2001.517">Oechsner et al 2001</a>].</p><p>Using [<sup>18</sup>F]-FDG (2-fluoro-2-deoxy-glucose) PET, bilaterally reduced striatal glucose uptake was found in all symptomatic individuals with MLS [<a class="bk_pop" href="#mcleod.REF.jung.2001a.384">Jung et al 2001a</a>, <a class="bk_pop" href="#mcleod.REF.oechsner.2001.517">Oechsner et al 2001</a>]. Quantitative FDG-PET also demonstrated reduced striatal glucose uptake in asymptomatic males with the McLeod blood group <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> and in female heterozygotes [<a class="bk_pop" href="#mcleod.REF.jung.2001a.384">Jung et al 2001a</a>, <a class="bk_pop" href="#mcleod.REF.oechsner.2001.517">Oechsner et al 2001</a>]. The degree of reduction of striatal glucose uptake also correlated with disease duration [<a class="bk_pop" href="#mcleod.REF.jung.2001a.384">Jung et al 2001a</a>].</p><p><b>Muscle biopsy</b> shows myopathic as well as neurogenic alterations, which were predominant in most studies:</p><ul><li class="half_rhythm"><div>Several studies demonstrated fiber type grouping, type 1 fiber predominance, type 2 fiber atrophy, increased variability in fiber size, and increased central nucleation [<a class="bk_pop" href="#mcleod.REF.swash.1983.717">Swash et al 1983</a>, <a class="bk_pop" href="#mcleod.REF.jung.2001b.1346">Jung et al 2001b</a>].</div></li><li class="half_rhythm"><div>In a series of ten individuals with MLS, including the original index patient, all had abnormal muscle histology: four had clear but nonspecific myopathic changes; however, all had neurogenic changes of variable degree consistent with predominant neurogenic muscle atrophy [<a class="bk_pop" href="#mcleod.REF.hewer.2007.3285">Hewer et al 2007</a>].</div></li><li class="half_rhythm"><div>One individual with an <i>XK</i> pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant had normal histologic and immunohistochemical findings [<a class="bk_pop" href="#mcleod.REF.jung.2003.928">Jung et al 2003</a>].</div></li><li class="half_rhythm"><div>In muscle of healthy individuals, Kell antigen was located in the sarcoplasmic membranes and Kx immunohistochemistry revealed type 2 fiber-specific intracellular staining most probably confined to the sarcoplasmic reticulum. Muscle in males with MLS revealed no expression of Kx or Kell [<a class="bk_pop" href="#mcleod.REF.jung.2001b.1346">Jung et al 2001b</a>].</div></li></ul><p><b>Nerve histology.</b> Nerve biopsy may demonstrate a chronic axonal neuropathy with prominent regenerative activity and selective loss of large myelinated fibers [<a class="bk_pop" href="#mcleod.REF.dotti.2004">Dotti et al 2004</a>].</p><p>Postmortem motor and sensory nerve examinations demonstrated axonal motor neuropathy [<a class="bk_pop" href="#mcleod.REF.hewer.2007.3285">Hewer et al 2007</a>].</p><p><b>Brain pathology.</b> Data from four individuals with MLS (3 males and 1 manifesting female <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a>) are available [<a class="bk_pop" href="#mcleod.REF.hardie.1991.13">Hardie et al 1991</a>, <a class="bk_pop" href="#mcleod.REF.danek.2008">Danek et al 2008</a>, <a class="bk_pop" href="#mcleod.REF.geser.2008">Geser et al 2008</a>]:</p><ul><li class="half_rhythm"><div>In the manifesting female <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, marked striatal atrophy was noted, corresponding to nonspecific loss of nerve cells and reactive astrocytic gliosis with predominant alterations in the head of the caudate nucleus [<a class="bk_pop" href="#mcleod.REF.hardie.1991.13">Hardie et al 1991</a>].</div></li><li class="half_rhythm"><div>In two males similar alterations were found with severe atrophy of the striatum and (less pronounced) of the globus pallidus [<a class="bk_pop" href="#mcleod.REF.danek.2008">Danek et al 2008</a>, <a class="bk_pop" href="#mcleod.REF.geser.2008">Geser et al 2008</a>]. Marked neuronal loss and astrocytic gliosis were observed on histologic examination. Moderate focal subcortical and subtle cortical astrocytic gliosis, particularly in frontal areas, was noted.</div></li><li class="half_rhythm"><div>In contrast to <a href="/books/n/gene/chac/">chorea-acanthocytosis</a> (ChAc), none of the four individuals with MLS demonstrated pathology in the thalamus or substantia nigra. Neither Lewy bodies nor definite abnormalities in other brain areas (e.g., the cortex) were observed.</div></li></ul></div></div><div id="mcleod.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Data presently available are insufficient to draw conclusions about <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> in McLeod neuroacanthocytosis syndrome [<a class="bk_pop" href="#mcleod.REF.danek.2001a.755">Danek et al 2001a</a>]. MLS shows considerable phenotypic variability, even between family members with identical <i>XK</i> variants [<a class="bk_pop" href="#mcleod.REF.danek.2001b.882">Danek et al 2001b</a>, <a class="bk_pop" href="#mcleod.REF.walker.2007a.299">Walker et al 2007a</a>].</p><p>Only three pathogenic <i>XK</i> <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants have a possible <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>-<a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> correlation. Although rare, they are potentially useful in the elucidation of structural and functional relationships. For more details, see <a class="figpopup" href="/books/NBK1354/table/mcleod.T.notable_xk_pathogenic_variants/?report=objectonly" target="object" rid-figpopup="figmcleodTnotablexkpathogenicvariants" rid-ob="figobmcleodTnotablexkpathogenicvariants">Table 6</a>.</p><ul><li class="half_rhythm"><div>The <a class="figpopup" href="/books/NBK1354/table/mcleod.T.notable_xk_pathogenic_variants/?report=objectonly" target="object" rid-figpopup="figmcleodTnotablexkpathogenicvariants" rid-ob="figobmcleodTnotablexkpathogenicvariants">c.979G&#x0003e;A</a> variant was associated with an <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> immunohematologic <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> without evidence for muscular, central, and peripheral nervous system involvement [<a class="bk_pop" href="#mcleod.REF.jung.2003.928">Jung et al 2003</a>].</div></li><li class="half_rhythm"><div>An individual with the <a class="figpopup" href="/books/NBK1354/table/mcleod.T.notable_xk_pathogenic_variants/?report=objectonly" target="object" rid-figpopup="figmcleodTnotablexkpathogenicvariants" rid-ob="figobmcleodTnotablexkpathogenicvariants">c.664C&#x0003e;G</a> variant did not show significant neurologic or systemic abnormalities [<a class="bk_pop" href="#mcleod.REF.walker.2007b.244">Walker et al 2007b</a>].</div></li><li class="half_rhythm"><div>A single-base substitution in an <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> near a splice junction (c.508+5G&#x0003e;A, resulting in alternative <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> and some degree of normal splicing) did not lead to any significant neurologic abnormalities [<a class="bk_pop" href="#mcleod.REF.walker.2007b.244">Walker et al 2007b</a>].</div></li></ul></div><div id="mcleod.Penetrance"><h3>Penetrance</h3><p>In males, the <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of neurologic and neuromuscular manifestations of MLS is high &#x02013; perhaps even complete &#x02013; after age 50 years. Available data indicate that most males with the McLeod blood group <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> will develop clinical manifestations of McLeod neuroacanthocytosis syndrome [<a class="bk_pop" href="#mcleod.REF.bertelson.1988.703">Bertelson et al 1988</a>, <a class="bk_pop" href="#mcleod.REF.hardie.1991.13">Hardie et al 1991</a>, <a class="bk_pop" href="#mcleod.REF.danek.2001a.755">Danek et al 2001a</a>, <a class="bk_pop" href="#mcleod.REF.jung.2001b.1346">Jung et al 2001b</a>]. In a few individuals, however, neurologic and neuromuscular manifestations may be absent or only minor even after long-term follow up [<a class="bk_pop" href="#mcleod.REF.jung.2003.928">Jung et al 2003</a>, <a class="bk_pop" href="#mcleod.REF.walker.2007b.244">Walker et al 2007b</a>].</p><p>In the past, many reports (including that of the index case) described only hematologic findings, and no neurologic or neuroimaging workup was performed in these individuals [<a class="bk_pop" href="#mcleod.REF.allen.1961.555">Allen et al 1961</a>, <a class="bk_pop" href="#mcleod.REF.symmans.1979.575">Symmans et al 1979</a>, <a class="bk_pop" href="#mcleod.REF.bertelson.1988.703">Bertelson et al 1988</a>, <a class="bk_pop" href="#mcleod.REF.lee.2000.93">Lee et al 2000</a>]. However, in many of these individuals neurologic manifestations were identified during long-term follow up [<a class="bk_pop" href="#mcleod.REF.bertelson.1988.703">Bertelson et al 1988</a>, <a class="bk_pop" href="#mcleod.REF.danek.2001a.755">Danek et al 2001a</a>].</p></div><div id="mcleod.Nomenclature"><h3>Nomenclature</h3><p>The term "neuroacanthocytosis" refers to several genetically and phenotypically distinct disorders [<a class="bk_pop" href="#mcleod.REF.danek.2004">Danek et al 2004</a>, <a class="bk_pop" href="#mcleod.REF.danek.2005.171">Danek et al 2005</a>]; see <a href="#mcleod.Differential_Diagnosis">Differential Diagnosis</a>.</p><p>The term "McLeod blood group <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>" (named after the first <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>, Hugh McLeod) describes the immunohematologic abnormalities consisting of absent expression of Kx RBC antigen and reduced expression of Kell RBC antigens in the index case originally described by <a class="bk_pop" href="#mcleod.REF.allen.1961.555">Allen et al [1961]</a>.</p><p>The terms "Kell blood group precursor" and "Kell blood group precursor substance" for the XK protein or the Kx RBC antigen, respectively, are incorrect and no longer in use.</p></div><div id="mcleod.Prevalence"><h3>Prevalence</h3><p>The prevalence of MLS cannot be determined based on the data available from the approximately 250 cases known worldwide. The prevalence is estimated at 1:10,000,000 [<a class="bk_pop" href="#mcleod.REF.walker.2019.158">Walker et al 2019</a>].</p></div></div><div id="mcleod.Genetically_Related_Allelic_Disor"><h2 id="_mcleod_Genetically_Related_Allelic_Disor_">Genetically Related (Allelic) Disorders</h2><p>No other phenotypes are known to be caused by pathogenic variants in <i>XK</i> alone.</p><p><b>Contiguous-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> rearrangements.</b> Other genes that lie in close proximity to <i>XK</i> at Xp21.1 and the disorders caused by their <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> include the following [<a class="bk_pop" href="#mcleod.REF.peng.2007.142">Peng et al 2007</a>]:</p><ul><li class="half_rhythm"><div>5' of <i>XK</i> on Xp21.1: <i>DMD</i> (<a href="/books/n/gene/dbmd/">Duchenne muscular dystrophy</a>)</div></li><li class="half_rhythm"><div>3' of <i>XK</i> on Xp21.1:</div><ul><li class="half_rhythm"><div><i>CYBB</i> (<a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> <a href="/books/n/gene/cgd/">chronic granulomatous disease</a>)</div></li><li class="half_rhythm"><div><i>RPGR</i> (<i>RPGR</i>-related <a href="/books/n/gene/rp-overview/">retinitis pigmentosa</a>)</div></li><li class="half_rhythm"><div><i>OTC</i> (<a href="/books/n/gene/otc-def/">ornithine transcarbamylase deficiency</a>)</div></li></ul></li></ul><p>Note: Concurrent <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of <i>CYBB</i> and <i>XK</i> is the most common; deletion of all five genes is exceedingly rare.</p></div><div id="mcleod.Differential_Diagnosis"><h2 id="_mcleod_Differential_Diagnosis_">Differential Diagnosis</h2><div id="mcleod.T.other_genes_of_interest_in_the" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Other Genes of Interest in the Differential Diagnosis of McLeod Neuroacanthocytosis Syndrome (MLS)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1354/table/mcleod.T.other_genes_of_interest_in_the/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mcleod.T.other_genes_of_interest_in_the_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene</th><th id="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_2" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_3" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:middle;">Clinical Features of Differential Diagnosis Disorder</th></tr><tr><th headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4" id="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Overlapping w/MLS</th><th headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4" id="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distinguishing from MLS</th></tr></thead><tbody><tr><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HTT</i></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/huntington/">Huntington disease</a><br />(HD)</td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>May appear indistinguishable from MLS</div></li><li class="half_rhythm"><div>Progressive choreatic movement disorder</div></li><li class="half_rhythm"><div>Cognitive &#x00026; psychiatric disturbances</div></li></ul>
</td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Anticipation</div></li><li class="half_rhythm"><div>Absence of seizures, myopathy, &#x00026; cardiomyopathy</div></li></ul>
</td></tr><tr><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_1 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_2 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_3 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_1 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_2" colspan="5" scope="col" rowspan="1" style="text-align:left;vertical-align:top;"><b>Neuroacanthocytosis syndromes&#x000a0;<sup>1</sup> assoc w/lipid malabsorption primarily affecting spinal cord, cerebellum, &#x00026; PNS&#x000a0;<sup>2</sup></b></td></tr><tr><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ANGPTL3</i></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypobetalipoproteinemia type 2<br />(OMIM <a href="https://omim.org/entry/605019" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">605019</a>)&#x000a0;<sup>2</sup></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_1" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Acanthocytosis</div></li><li class="half_rhythm"><div>Dysarthria</div></li><li class="half_rhythm"><div>Neuropathy</div></li><li class="half_rhythm"><div>Areflexia</div></li></ul>
</td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_2" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Pigmentary retinopathy</div></li><li class="half_rhythm"><div>Absence of basal ganglia involvement</div></li></ul>
</td></tr><tr><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>APOB</i></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypobetalipoproteinemia type 1<br />(OMIM <a href="https://omim.org/entry/615558" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">615558</a>)&#x000a0;<sup>2</sup></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td></tr><tr><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>MTTP</i></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Abetalipoproteinemia<br />(Bassen-Kornzweig disease)&#x000a0;<sup>2</sup></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td></tr><tr><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_1 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_2 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_3 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_1 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_2" colspan="5" scope="col" rowspan="1" style="text-align:left;vertical-align:top;"><b>Neuroacanthocytosis syndromes predominantly affecting CNS (esp basal ganglia)&#x000a0;<sup>3</sup></b></td></tr><tr><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>JPH3</i></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/hd-l2/">HDL2</a></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Progressive course</div></li><li class="half_rhythm"><div>Dystonia</div></li><li class="half_rhythm"><div>Presentation w/chorea or parkinsonism may change w/evolution of the disease</div></li></ul>
</td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Almost all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals reported to date have been of African ancestry</div></li><li class="half_rhythm"><div>RBC acanthocytes not substantiated&#x000a0;<sup>5</sup></div></li></ul>
</td></tr><tr><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PANK2</i></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/pkan/">PKAN</a>; including HARP&#x000a0;<sup>4</sup><br />(see also <a href="/books/n/gene/nbia-ov/">Neurodegeneration with Brain Iron Accumulation Disorders Overview</a>)</td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Progressive dystonia</div></li><li class="half_rhythm"><div>Dysarthria</div></li><li class="half_rhythm"><div>Rigidity</div></li><li class="half_rhythm"><div>In ~25% of individuals: "atypical" presentation w/onset age &#x0003e;10 yrs, prominent speech defects, psychiatric disturbance, &#x00026; more gradual disease progression</div></li><li class="half_rhythm"><div>In &#x02265;8%: acanthocytosis</div></li></ul>
</td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Usually childhood or adolescent onset</div></li><li class="half_rhythm"><div>Basal ganglia iron deposition</div></li><li class="half_rhythm"><div>"Eye of the tiger" sign on MRI characteristic</div></li><li class="half_rhythm"><div>Pigmentary retinopathy</div></li></ul>
</td></tr><tr><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PRNP</i></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">HDL1<br />(OMIM <a href="https://www.omim.org/entry/603218" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">603218</a>)</td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Phenotype may be indistinguishable from HD.</td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Rapidly progressive course</div></li><li class="half_rhythm"><div>No hematologic, neuromuscular, or cardiac manifestations</div></li></ul>
</td></tr><tr><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>VPS13A</i></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/chac/">Chorea-acanthocytosis</a><br />(ChAc)</td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Progressive movement disorder (primarily chorea)</div></li><li class="half_rhythm"><div>Subclinical myopathy &#x02192; progressive distal muscle wasting &#x00026; weakness</div></li><li class="half_rhythm"><div>Mental changes</div></li><li class="half_rhythm"><div>Seizures</div></li><li class="half_rhythm"><div>Progressive cognitive &#x00026; behavioral changes that resemble a frontal lobe syndrome</div></li><li class="half_rhythm"><div>Dystonia affecting trunk &#x00026; esp oral region &#x00026; tongue &#x02192; dysarthria &#x00026; serious dysphagia w/resultant weight loss</div></li></ul>
</td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>May present w/a parkinsonian syndrome</div></li><li class="half_rhythm"><div>Habitual tongue &#x00026; lip biting characteristic</div></li></ul>
</td></tr><tr><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_1 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_2 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_3 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_1 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_2" colspan="5" scope="col" rowspan="1" style="text-align:left;vertical-align:top;"><b>Other disorders</b></td></tr><tr><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ATN1</i></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/drpla/">DRPLA</a></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ATP7B</i></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/wilson/">Wilson disease</a></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ATXN3</i></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/sca3/">SCA3</a></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CP</i></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/acp/">Aceruloplasminemia</a></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/acp/">Aceruloplasminemia</a> could be considered a neurodegeneration w/brain iron accumulation.&#x000a0;<sup>6</sup></td></tr><tr><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>DYT3</i></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/xdp/">X-linked dystonia-parkinsonism</a><br />(DYT3, DYT-TAF1, Lubag)</td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XL</td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>FTL</i></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/neuroferritin/">Neuroferritinopathy</a></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HPRT1</i></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/lns/">Lesch-Nyhan syndrome</a></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XL</td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>NKX2-1</i></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Benign hereditary chorea<br />(see <a href="/books/n/gene/nkx2-1-dis/"><i>NKX2-1-</i>Related Disorders</a>)</td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PLA2G6</i></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/inad/"><i>PLA2G6</i>-associated neurodegeneration</a><br />(infantile neuroaxonal dystrophy; Karak syndrome)</td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>TBP</i></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/sca17/">SCA17</a></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_1_4 hd_h_mcleod.T.other_genes_of_interest_in_the_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; CNS = central nervous system; DRPLA = dentatorubral-pallidoluysian atrophy; HDL = Huntington disease-like; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>; PKAN = pantothenate kinase-associated neurodegeneration; PNS = peripheral nervous system; SCA = spinocerebellar ataxia; XL = <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a></p></div></dd><dt>1. </dt><dd><div id="mcleod.TF.2.1"><p class="no_margin">Neurologic disorders associated with RBC acanthocytosis have been summarized as neuroacanthocytosis syndromes [<a class="bk_pop" href="#mcleod.REF.danek.2004">Danek et al 2004</a>, <a class="bk_pop" href="#mcleod.REF.danek.2005.171">Danek et al 2005</a>, <a class="bk_pop" href="#mcleod.REF.jung.2011.68">Jung et al 2011</a>].</p></div></dd><dt>2. </dt><dd><div id="mcleod.TF.2.2"><p class="no_margin">Neurologic findings include: <br />a. A progressive spinocerebellar degeneration with gait ataxia, dysmetria, and dysarthria; <br />b. A demyelinating sensorimotor and axonal peripheral neuropathy with hyporeflexia and diminished vibration and position sense;<br />c. Rarely, pyramidal tract signs; and <br />d. Rarely, cranial nerve involvement [<a class="bk_pop" href="#mcleod.REF.kane.1995">Kane &#x00026; Havel 1995</a>, <a class="bk_pop" href="#mcleod.REF.tarugi.2011.81">Tarugi &#x00026; Averna 2011</a>].</p></div></dd><dt>3. </dt><dd><div id="mcleod.TF.2.3"><p class="no_margin">Results in a chorea syndrome resembling Huntington disease</p></div></dd><dt>4. </dt><dd><div id="mcleod.TF.2.4"><p class="no_margin">HARP syndrome (<i>h</i>ypoprebetalipoproteinemia, <i>a</i>canthocytosis, <i>r</i>etinitis pigmentosa, and <i>p</i>allidal degeneration) is allelic with PKAN [<a class="bk_pop" href="#mcleod.REF.ching.2002.1673">Ching et al 2002</a>, <a class="bk_pop" href="#mcleod.REF.houlden.2003.1423">Houlden et al 2003</a>]. The continued use of this term is discouraged particularly since "hypoprebetalipoproteinemia" is not a meaningful entity.</p></div></dd><dt>5. </dt><dd><div id="mcleod.TF.2.5"><p class="no_margin"><a class="bk_pop" href="#mcleod.REF.anderson.2017.512">Anderson et al [2017]</a></p></div></dd><dt>6. </dt><dd><div id="mcleod.TF.2.6"><p class="no_margin"><a class="bk_pop" href="#mcleod.REF.kassubek.2017.151">Kassubek et al [2017]</a></p></div></dd></dl></div></div></div></div><div id="mcleod.Management"><h2 id="_mcleod_Management_">Management</h2><div id="mcleod.Evaluations_Following_Initial_Dia"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease in an individual diagnosed with McLeod neuroacanthocytosis syndrome (MLS), the evaluations summarized in <a class="figpopup" href="/books/NBK1354/table/mcleod.T.recommended_evaluations_followi/?report=objectonly" target="object" rid-figpopup="figmcleodTrecommendedevaluationsfollowi" rid-ob="figobmcleodTrecommendedevaluationsfollowi">Table 3</a> (if not performed as part of the evaluation that led to the diagnosis) are recommended.</p><div id="mcleod.T.recommended_evaluations_followi" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Recommended Evaluations Following Initial Diagnosis in Individuals with McLeod Neuroacanthocytosis Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1354/table/mcleod.T.recommended_evaluations_followi/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mcleod.T.recommended_evaluations_followi_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_mcleod.T.recommended_evaluations_followi_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_mcleod.T.recommended_evaluations_followi_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_mcleod.T.recommended_evaluations_followi_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment</th></tr></thead><tbody><tr><td headers="hd_h_mcleod.T.recommended_evaluations_followi_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Neurologic</b></td><td headers="hd_h_mcleod.T.recommended_evaluations_followi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">For movement disorder</td><td headers="hd_h_mcleod.T.recommended_evaluations_followi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Choreiform movements; head drops; apply unified Huntington Disease Rating Scale (UHDRS) &#x00026; perform brain MRI</td></tr><tr><td headers="hd_h_mcleod.T.recommended_evaluations_followi_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">For seizures</td><td headers="hd_h_mcleod.T.recommended_evaluations_followi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Usually generalized seizures; perform EEG&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_mcleod.T.recommended_evaluations_followi_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">For neuromuscular involvement</td><td headers="hd_h_mcleod.T.recommended_evaluations_followi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Absent DTRs, muscle weakness or atrophy; determine serum CK, ALT, AST, &#x00026; LDH levels; EMG &#x00026; NCV studies</td></tr><tr><td headers="hd_h_mcleod.T.recommended_evaluations_followi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Cognitive</b></td><td headers="hd_h_mcleod.T.recommended_evaluations_followi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To include motor, speech/language evaluation, &#x00026; general cognitive skills</td><td headers="hd_h_mcleod.T.recommended_evaluations_followi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Frontotemporal &#x00026; executive deficits; perform formal neuropsychological evaluation &#x00026;/or Montreal cognitive assessment</td></tr><tr><td headers="hd_h_mcleod.T.recommended_evaluations_followi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Psychiatric</b></td><td headers="hd_h_mcleod.T.recommended_evaluations_followi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">For frontal-type deficits; personality disorder, anxiety, depression, obsessive-compulsive disorder, bipolar disorder, schizo-affective disorder</td><td headers="hd_h_mcleod.T.recommended_evaluations_followi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Perform standardized psychiatric assessment; evaluation of symptom-oriented psychotherapeutic &#x00026; psychopharmacologic interventions. Contact w/a patient advocacy organization may provide additional benefit.&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_mcleod.T.recommended_evaluations_followi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Feeding</b></td><td headers="hd_h_mcleod.T.recommended_evaluations_followi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Feeding/nutritional assessment</td><td headers="hd_h_mcleod.T.recommended_evaluations_followi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Feeding dystonia; consider clinical &#x00026;/or fiberoptic feeding evaluation</td></tr><tr><td headers="hd_h_mcleod.T.recommended_evaluations_followi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Cardiac</b></td><td headers="hd_h_mcleod.T.recommended_evaluations_followi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dilated cardiomyopathy, atrial fibrillation, tachyarrhythmia</td><td headers="hd_h_mcleod.T.recommended_evaluations_followi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Usually develop over time&#x000a0;<sup>1</sup>; perform echocardiography &#x00026;Holter-ECG</td></tr><tr><td headers="hd_h_mcleod.T.recommended_evaluations_followi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Hematologic</b></td><td headers="hd_h_mcleod.T.recommended_evaluations_followi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Immunohematologic evaluation: erythrocyte phenotyping for Kell &#x00026; Kx antigens; expression of Kell protein by flow cytometry, search for anti-public alloantibodies, direct antiglobulin test&#x000a0;<sup>3</sup></td><td headers="hd_h_mcleod.T.recommended_evaluations_followi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191; risk of transfusion reactions w/repetitive blood transfusions; consider autologous blood banking when planned surgery may require blood transfusions.</td></tr><tr><td headers="hd_h_mcleod.T.recommended_evaluations_followi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Miscellaneous/</b><br /><b>Other</b></td><td headers="hd_h_mcleod.T.recommended_evaluations_followi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consultation w/clinical geneticist &#x00026;/or genetic counselor</td><td headers="hd_h_mcleod.T.recommended_evaluations_followi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">DTRs = deep tendon reflexes; EEG= electroencephalogram</p></div></dd><dt>1. </dt><dd><div id="mcleod.TF.3.1"><p class="no_margin">Early recognition and treatment of cardiac manifestations and seizures are important, as these potential complications may be severe and could cause premature death [<a class="bk_pop" href="#mcleod.REF.danek.2001a.755">Danek et al 2001a</a>, <a class="bk_pop" href="#mcleod.REF.hewer.2007.3285">Hewer et al 2007</a>, <a class="bk_pop" href="#mcleod.REF.walker.2019.158">Walker et al 2019</a>].</p></div></dd><dt>2. </dt><dd><div id="mcleod.TF.3.2"><p class="no_margin"><a class="bk_pop" href="#mcleod.REF.irvine.2013">Irvine &#x00026; Irvine [2013]</a></p></div></dd><dt>3. </dt><dd><div id="mcleod.TF.3.3"><p class="no_margin"><a class="bk_pop" href="#mcleod.REF.frey.2015.277">Frey et al [2015]</a></p></div></dd></dl></div></div></div></div><div id="mcleod.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><div id="mcleod.T.treatment_of_manifestations_in" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Treatment of Manifestations in Individuals with McLeod Neuroacanthocytosis Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1354/table/mcleod.T.treatment_of_manifestations_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mcleod.T.treatment_of_manifestations_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_mcleod.T.treatment_of_manifestations_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Manifestation/<br />Concern</th><th id="hd_h_mcleod.T.treatment_of_manifestations_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment</th><th id="hd_h_mcleod.T.treatment_of_manifestations_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Considerations/Other</th></tr></thead><tbody><tr><td headers="hd_h_mcleod.T.treatment_of_manifestations_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Chorea</b></td><td headers="hd_h_mcleod.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Dopamine antagonists incl tiapride, clozapine, or quetiapine</div></li><li class="half_rhythm"><div>Dopamine depletor: tetrabenazine</div></li></ul>
</td><td headers="hd_h_mcleod.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Avoid use of typical neuroleptics (e.g., haloperidol) because of risk of extrapyramidal adverse events.</td></tr><tr><td headers="hd_h_mcleod.T.treatment_of_manifestations_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Seizures</b></td><td headers="hd_h_mcleod.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Antiepileptic drugs&#x000a0;<sup>1</sup></td><td headers="hd_h_mcleod.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Avoid long-term use of benzodiazepines because of possible negative effect on neuromuscular system.</td></tr><tr><td headers="hd_h_mcleod.T.treatment_of_manifestations_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Neuromuscular</b></td><td headers="hd_h_mcleod.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Physiotherapy</div></li><li class="half_rhythm"><div>Sufficient supplementation of calories &#x00026; protein</div></li><li class="half_rhythm"><div>Supplementation of vitamins D &#x00026; B<sub>12</sub> if needed</div></li></ul>
</td><td headers="hd_h_mcleod.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Endurance exercise as tolerated may be helpful.</div></li><li class="half_rhythm"><div>Avoid strength exercises, in particular of the eccentric type.</div></li></ul>
</td></tr><tr><td headers="hd_h_mcleod.T.treatment_of_manifestations_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Cognitive</b></td><td headers="hd_h_mcleod.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cognitive training is probably rarely indicated.</td><td headers="hd_h_mcleod.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consider counseling as needed based on daily living &#x00026;/or work-related requirements, incl job alternatives.</td></tr><tr><td headers="hd_h_mcleod.T.treatment_of_manifestations_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Psychiatric</b></td><td headers="hd_h_mcleod.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Standard treatment according to manifestation</td><td headers="hd_h_mcleod.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Extended &#x00026; continuous multidisciplinary psychosocial support for <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals &#x00026; families</td></tr><tr><td headers="hd_h_mcleod.T.treatment_of_manifestations_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Cardiac</b></td><td headers="hd_h_mcleod.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Standard treatment according to clinical &#x00026;/or ECG presentation</td><td headers="hd_h_mcleod.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_mcleod.T.treatment_of_manifestations_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Hematologic</b></td><td headers="hd_h_mcleod.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Avoid transfusion of Kx+ homologous blood products.</td><td headers="hd_h_mcleod.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Avoid repetitive blood transfusions; Consider cryopreservation of Kx- autologous blood for future use.</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="mcleod.TF.4.1"><p class="no_margin">When epilepsy is suspected, EEG should be performed and AED treatment considered (based on standard guidelines including the monitoring of medication-specific laboratory parameters and serum concentrations). Because of the increased risk of rhabdomyolysis, treatment with neuroleptics &#x02013; in particular clozapine &#x02013; should be carefully monitored, both clinically and with serum CK measurements.</p></div></dd></dl></div></div></div></div><div id="mcleod.Surveillance"><h3>Surveillance</h3><div id="mcleod.T.recommended_surveillance_for_in" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Recommended Surveillance for Individuals with McLeod Neuroacanthocytosis Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1354/table/mcleod.T.recommended_surveillance_for_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mcleod.T.recommended_surveillance_for_in_lrgtbl__"><table><thead><tr><th id="hd_h_mcleod.T.recommended_surveillance_for_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_mcleod.T.recommended_surveillance_for_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_mcleod.T.recommended_surveillance_for_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Frequency</th></tr></thead><tbody><tr><td headers="hd_h_mcleod.T.recommended_surveillance_for_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Cardiac</b></td><td headers="hd_h_mcleod.T.recommended_surveillance_for_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cardiac examinations (Holter ECG &#x00026; echocardiography)</td><td headers="hd_h_mcleod.T.recommended_surveillance_for_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Initially every 2-3 yrs; more frequently if abnormal clinical findings &#x00026;/or cardiac examinations</td></tr><tr><td headers="hd_h_mcleod.T.recommended_surveillance_for_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Seizures</b></td><td headers="hd_h_mcleod.T.recommended_surveillance_for_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">EEG</td><td headers="hd_h_mcleod.T.recommended_surveillance_for_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Whenever new-onset seizures are suspected</td></tr><tr><td headers="hd_h_mcleod.T.recommended_surveillance_for_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Muscle</b><br /><b>(rhabdomyolysis)</b></td><td headers="hd_h_mcleod.T.recommended_surveillance_for_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Serum CK concentration</td><td headers="hd_h_mcleod.T.recommended_surveillance_for_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Regularly, in particular when under neuroleptic treatment</td></tr></tbody></table></div></div></div><div id="mcleod.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Blood transfusions with Kx antigens should be avoided in males with the McLeod blood group <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Kx-negative blood or, if possible, banked autologous blood should be used for transfusions. Note that because <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females have both Kx+ and Kx- red blood cells, they can be transfused with Kx+ homologous blood products.</p></div><div id="mcleod.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to clarify the genetic status of apparently asymptomatic at-risk relatives of any age in order to identify as early as possible those who would benefit from: (1) detailed blood compatibility information to prevent transfusion of Kx+ homologous blood products, and (2) possible prophylactic cryopreservation of autologous blood for use in future transfusions.</p><p>See <a href="#mcleod.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="mcleod.Pregnancy_Management"><h3>Pregnancy Management</h3><p>In female heterozygotes, the probability of manifestations of the McLeod neuroacanthocytosis syndrome in the reproductive period is presumably very low; thus, no particular recommendations can be made.</p></div><div id="mcleod.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="mcleod.Genetic_Counseling"><h2 id="_mcleod_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="mcleod.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>McLeod neuroacanthocytosis syndrome (MLS) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner.</p></div><div id="mcleod.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The father of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male will not have the disease nor will he be <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> for the <i>XK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; therefore, he does not require further evaluation/testing.</div></li><li class="half_rhythm"><div>In a family with more than one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual, the mother of an affected male is an <a class="def" href="/books/n/gene/glossary/def-item/obligate-heterozygote/">obligate heterozygote</a>.</div></li><li class="half_rhythm"><div>If a male is the only <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member (i.e., a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case), the mother may be a <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> or the affected male may have a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>XK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, in which case the mother is not a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>. One <i>de novo</i>
<i>XK</i> pathogenic variant has been described in MLS [<a class="bk_pop" href="#mcleod.REF.supple.2001.369">Supple et al 2001</a>].</div></li><li class="half_rhythm"><div>If a woman has more than one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> son and the <i>XK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in her leukocyte DNA, she may have <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>. No data regarding germline mosaicism in MLS are available to date.</div></li></ul><p><b>Sibs of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to sibs depends on the genetic status of the mother:</p><ul><li class="half_rhythm"><div class="half_rhythm">If the mother of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the chance of transmitting it in each pregnancy is 50%. Males who inherit the variant will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; females who inherit the variant will be heterozygotes and will usually not be affected. Significant interfamilial phenotypic variability has been observed in MLS (see <a href="#mcleod.Clinical_Description">Clinical Description</a>).</div><div class="half_rhythm">Females <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for <i>XK</i> pathogenic variants have <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> for the Kell and Kx blood group antigens but usually lack CNS and neuromuscular manifestations. However, some heterozygous females may develop clinical manifestations including chorea or late-onset cognitive decline.</div></li><li class="half_rhythm"><div class="half_rhythm">If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> represents a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case (i.e., a single occurrence in a family) and if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in the leukocyte DNA of the mother, the risk to sibs is low but greater than that of the general population because of the theoretic possibility of maternal <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Affected males transmit the <i>XK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> to:</p><ul><li class="half_rhythm"><div>All of their daughters who will be heterozygotes and usually will not be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> (see Clinical Characteristics, <a href="#mcleod.Females">Females</a>);</div></li><li class="half_rhythm"><div>None of their sons.</div></li></ul><p><b>Other family members.</b> A male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s maternal aunts may be at risk of being heterozygotes and the aunt's offspring, depending on their gender, may be at risk of being heterozygotes or of being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</p></div><div id="mcleod.Heterozygote_Carrier_Detection"><h3>Heterozygote (Carrier) Detection</h3><p>Identification of female heterozygotes requires either (a) prior identification of the <i>XK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family or, (b) if an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male is not available for testing, either <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> first by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, and if no <i>XK</i> pathogenic variant is identified, by <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> or flow cytometric analysis of Kx and Kell erythrocyte antigens.</p><p>Note: Heterozygous females may very rarely develop clinical manifestations such as chorea or late-onset cognitive decline [<a class="bk_pop" href="#mcleod.REF.sveinsson.2018">Sveinsson et al 2018</a>].</p></div><div id="mcleod.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#mcleod.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early identification of those who would benefit from detailed blood compatibility information to prevent transfusion of Kx+ homologous blood products.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a></b>. When the mother of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> condition does not have the pathogenic variant identified in the proband, the pathogenic variant is likely <i>de novo</i>. However, non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-maternity/">alternate maternity</a> (e.g., with assisted reproduction) and undisclosed adoption could also be explored.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of genetic status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are heterozygotes, or are at risk of being heterozygotes.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="mcleod.Prenatal_Testing_and_Preimplantat"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>XK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for MLS are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="mcleod.Resources"><h2 id="_mcleod_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Advocacy for Neuroacanthocytosis Patients</b></div><div>39 Coleherne Court</div><div>London SW5 0DN</div><div>United Kingdom</div><div><b>Phone:</b> 44 (0) 20 7460-8874</div><div><b>Email:</b> ginger@naadvocacy.org; Jen@naadvocacy.org</div><div><a href="http://www.naadvocacy.org/welcome-advocacy-neuroacanthocytosis" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.naadvocacy.org</a></div></li><li class="half_rhythm"><div><b>Cardiomyopathy UK</b></div><div>Chiltern Court</div><div>Asheridge Road</div><div>Unit 10</div><div>Chesham Buckinghamshire HP5 2PX</div><div>United Kingdom</div><div><b>Phone:</b> 0800 018 1024 (UK only); 0800 018 1024 (UK only)</div><div><b>Email:</b> info@cardiomyopathy.org</div><div><a href="http://www.cardiomyopathy.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cardiomyopathy.org</a></div></li><li class="half_rhythm"><div><b>European Huntington's Disease Network (EHDN)</b></div><div>Germany</div><div><a href="http://www.ehdn.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ehdn.org</a></div></li><li class="half_rhythm"><div><b>Huntington's Disease Society of America (HDSA)</b></div><div><a href="http://www.hdsa.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.hdsa.org</a></div></li><li class="half_rhythm"><div><b>Neuroacanthocytosis Database (Registry)</b></div><div>Prof. Adrian Danek</div><div>Neurologische Klinik</div><div>POB 701260</div><div>Germany</div><div><b>Phone:</b> 49 (89) 4400-76676</div><div><b>Email:</b> adrian.danek@med.uni-muenchen.de</div><div><a href="https://www.euro-hd.net/html/na/registry" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.euro-hd.net/html/na/registry</a></div></li></ul></div><div id="mcleod.Molecular_Genetics"><h2 id="_mcleod_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="mcleod.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>McLeod Neuroacanthocytosis Syndrome: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1354/table/mcleod.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mcleod.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_mcleod.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_mcleod.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_mcleod.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_mcleod.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_mcleod.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_mcleod.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_mcleod.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/7504" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>XK</i></a></td><td headers="hd_b_mcleod.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=7504" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Xp21<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_mcleod.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P51811" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Membrane transport protein XK</a></td><td headers="hd_b_mcleod.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/XK" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">XK @ LOVD</a></td><td headers="hd_b_mcleod.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=XK" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">XK</a></td><td headers="hd_b_mcleod.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=XK[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">XK</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="mcleod.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="mcleod.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for McLeod Neuroacanthocytosis Syndrome (<a href="/omim/300842,314850" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1354/table/mcleod.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mcleod.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/300842" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">300842</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MCLEOD SYNDROME; MCLDS</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/314850" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">314850</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">KELL BLOOD GROUP PROTEIN, MCLEOD SYNDROME-ASSOCIATED; XK</td></tr></tbody></table></div></div><div id="mcleod.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p><i>XK</i> encodes XK, a red blood cell antigen. The XK protein has ten transmembrane domains and the structural characteristics of a membrane transport protein [<a class="bk_pop" href="#mcleod.REF.ho.1994.869">Ho et al 1994</a>]. The XK protein attaches to the Kell glycoprotein, encoded by <i>KEL</i> on <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 7, by a single disulfide bond (XK p.Cys347- Kell p.Cys72) when they are coexpressed [<a class="bk_pop" href="#mcleod.REF.russo.1998.13950">Russo et al 1998</a>]. In the red cell membrane, the heterodimeric protein-complex XK-KEL is part of the larger membrane multiprotein complex subunit 4.1 (MMPC4.1) containing Band3 glycoprotein, glycophorin C, Rh protein, Rh associated glycoprotein, and Duffy protein, which supports red cell cytoskeleton stability [<a class="bk_pop" href="#mcleod.REF.frey.2015.277">Frey et al 2015</a>, <a class="bk_pop" href="#mcleod.REF.lux.2016.187">Lux 2016</a>]. XK may also be important for transmembrane exchange of divalent cations (Ca++, Mg++) and Gardos channel function [<a class="bk_pop" href="#mcleod.REF.de_franceschi.2005.1454">De Franceschi et al 2005</a>, <a class="bk_pop" href="#mcleod.REF.rivera.2013.80">Rivera et al 2013</a>].</p><p>XK and Kell are predominantly coexpressed in erythroid tissues, but their expression in non-erythroid tissues differs. XK is ubiquitously expressed in many other tissues, especially in high amounts in skeletal muscle and brain [<a class="bk_pop" href="#mcleod.REF.russo.2000.340">Russo et al 2000</a>, <a class="bk_pop" href="#mcleod.REF.camaraclayette.2001.171">Camara-Clayette et al 2001</a>, <a class="bk_pop" href="#mcleod.REF.jung.2001b.1346">Jung et al 2001b</a>]; however, Kell is not present in brain and skeletal muscle in that species. XK is expressed in various cerebral regions, with high amounts in pontine region, olfactory lobe, and cerebellum [<a class="bk_pop" href="#mcleod.REF.lee.2007.365">Lee et al 2007</a>]. It has been proposed that the function of isolated XK in non-erythroid tissue differs from that of XK in combination with Kell.</p><p><b>Mechanism of disease causation.</b> McLeod neuroacanthocytosis syndrome occurs through a <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> mechanism.</p><p><b><i>XK</i>-specific laboratory technical considerations.</b> A naming convention for abnormal <i>XK</i> alleles has been established by the <a href="http://www.isbtweb.org/working-parties/red-cell-immunogenetics-and-blood-group-terminology/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">International Society of Blood Transfusion</a> (IBST; scroll down and select <b>Blood Group Allele Tables</b>, then <b>XK</b>). The XK protein reference <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is defined as XK*01. Alleles associated with MLS are defined as XK*N.# beginning with 01, with N indicating null and # being assigned to each reported abnormal allele (e.g., c.664C&#x0003e;G [p.Arg222Gly] is designated XK*N.27).</p><p>Note: Stepwise partitioning of Xp21 has been used as an alternative method to define the exact breakpoints of contiguous-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions [<a class="bk_pop" href="#mcleod.REF.gassner.2017.2125">Gassner et al 2017</a>, <a class="bk_pop" href="#mcleod.REF.sveinsson.2018">Sveinsson et al 2018</a>].</p><p><b>Notable <i>XK</i></b>
<b>variants.</b> All three of the reported pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants occurred in the transmembrane domains and on highly conserved amino-acid residues that are evolutionarily related to <i>XK</i>, suggesting possible important roles in structure or function. The p.Glu327 and p.Arg222 residues may be involved in the basic structure of <i>XK</i> rather than in its function; the p.Cys294 residue, which is conserved specifically in the <i>XK</i> family, may be critical for normal function [<a class="bk_pop" href="#mcleod.REF.walker.2007b.244">Walker et al 2007b</a>].</p><div id="mcleod.T.notable_xk_pathogenic_variants" class="table"><h3><span class="label">Table 6. </span></h3><div class="caption"><p>Notable <i>XK</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1354/table/mcleod.T.notable_xk_pathogenic_variants/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mcleod.T.notable_xk_pathogenic_variants_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_mcleod.T.notable_xk_pathogenic_variants_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th><th id="hd_h_mcleod.T.notable_xk_pathogenic_variants_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_mcleod.T.notable_xk_pathogenic_variants_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_mcleod.T.notable_xk_pathogenic_variants_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment [Reference]</th></tr></thead><tbody><tr><td headers="hd_h_mcleod.T.notable_xk_pathogenic_variants_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_021083.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_021083<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/protein/NP_066569.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_066569<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_h_mcleod.T.notable_xk_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.664C&#x0003e;G</td><td headers="hd_h_mcleod.T.notable_xk_pathogenic_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg222Gly<br />(XK*N.27)</td><td headers="hd_h_mcleod.T.notable_xk_pathogenic_variants_1_1_1_4" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;">The 3 reported <i>XK</i> <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants are predicted to disrupt either structure or function [<a class="bk_pop" href="#mcleod.REF.walker.2007b.244">Walker et al 2007b</a>].</td></tr><tr><td headers="hd_h_mcleod.T.notable_xk_pathogenic_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.880T&#x0003e;C</td><td headers="hd_h_mcleod.T.notable_xk_pathogenic_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Cys294Arg<br />(XK*N.28)</td></tr><tr><td headers="hd_h_mcleod.T.notable_xk_pathogenic_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.979G&#x0003e;A</td><td headers="hd_h_mcleod.T.notable_xk_pathogenic_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu327Lys<br />(XK*N.29)</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="mcleod.TF.6.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd></dl></div></div></div></div></div><div id="mcleod.References"><h2 id="_mcleod_References_">References</h2><div id="mcleod.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.allen.1961.555">Allen FH Jr, Krabbe SM, Corcoran PA. A new phenotype (McLeod) in the Kell blood-group system. <span><span class="ref-journal">Vox Sang. </span>1961;<span class="ref-vol">6</span>:555–60.</span> [<a href="/pubmed/13860532" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13860532</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.anderson.2017.512">Anderson DG, Carmona S, Naidoo K, Coetzer TL, Carr J, Rudnicki DD, Walker RH, Margolis RL, Krause A. Absence of acanthocytosis in Huntington's disease-like 2: a prospective comparison with Huntington's disease. <span><span class="ref-journal">Tremor Other Hyperkinet Mov (N Y). </span>2017;<span class="ref-vol">7</span>:512.</span> [<a href="/pmc/articles/PMC5721130/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5721130</span></a>] [<a href="/pubmed/29226019" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29226019</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.bertelson.1988.703">Bertelson CJ, Pogo AO, Chaudhuri A, Marsh WL, Redman CM, Banerjee D, Symmans WA, Simon T, Frey D, Kunkel LM. Localization of the McLeod locus (XK) within Xp21 by deletion analysis. <span><span class="ref-journal">Am J Hum Genet. </span>1988;<span class="ref-vol">42</span>:703–11.</span> [<a href="/pmc/articles/PMC1715185/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1715185</span></a>] [<a href="/pubmed/3358422" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3358422</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.camaraclayette.2001.171">Camara-Clayette V, Rahuel C, Lopez C, Hattab C, Verkarre V, Bertrand O, Cartron JP. Transcriptional regulation of the KEL gene and Kell protein expression in erythroid and non-erythroid cells. <span><span class="ref-journal">Biochem J. </span>2001;<span class="ref-vol">356</span>:171–80.</span> [<a href="/pmc/articles/PMC1221825/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1221825</span></a>] [<a href="/pubmed/11336649" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11336649</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.chauveau.2011.1562">Chauveau M, Damon-Perriere N, Jung H, Latxague C, Spampinato U, Burbaud P, Tison F. Head drops are also observed in the McLeod syndrome. <span><span class="ref-journal">Mov Disord. </span>2011;<span class="ref-vol">26</span>:1562–3.</span> [<a href="/pubmed/21469202" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21469202</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.ching.2002.1673">Ching KH, Westaway SK, Gitschier J, Higgins JJ, Hayflick SJ. HARP syndrome is allelic with pantothenate kinase-associated neurodegeneration. <span><span class="ref-journal">Neurology. </span>2002;<span class="ref-vol">58</span>:1673–4.</span> [<a href="/pubmed/12058097" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12058097</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.danek.2005.171">Danek A, Jung HH, Melone MA, Rampoldi L, Broccoli V, Walker RH. Neuroacanthocytosis: new developments in a neglected group of dementing disorders. <span><span class="ref-journal">J Neurol Sci. </span>2005;<span class="ref-vol">229-230</span>:171–86.</span> [<a href="/pubmed/15760637" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15760637</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.danek.2008">Danek A, Neumann M, Brin MF, Symmans WA, Hays AP. Cerebral involvement in McLeod syndrome: the first autopsy revisited. In: Walker RH, Saiki S, Danek A, eds. <em>Neuroacanthocytosis Syndromes II.</em> Heidelberg, Germany: Springer; 2008:205-15.</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.danek.2001a.755">Danek A, Rubio JP, Rampoldi L, Ho M, Dobson-Stone C, Tison F, Symmans WA, Oechsner M, Kalckreuth W, Watt JM, Corbett AJ, Hamdalla HH, Marshall AG, Sutton I, Dotti MT, Malandrini A, Walker RH, Daniels G, Monaco AP. McLeod neuroacanthocytosis: genotype and phenotype. <span><span class="ref-journal">Ann Neurol. </span>2001a;<span class="ref-vol">50</span>:755–64.</span> [<a href="/pubmed/11761473" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11761473</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.danek.2004">Danek A, Sheesley L, Tierney M, Uttner I, Grafman J. Cognitive and neuropsychiatric findings in McLeod syndrome and in chorea-acanthocytosis. In: Danek A, ed. <em>Neuroacanthocytosis Syndromes</em>. Dordrecht, Netherlands: Springer; 2004:95-115.</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.danek.2001b.882">Danek A, Tison F, Rubio J, Oechsner M, Kalckreuth W, Monaco AP. The chorea of McLeod syndrome. <span><span class="ref-journal">Mov Disord. </span>2001b;<span class="ref-vol">16</span>:882–9.</span> [<a href="/pubmed/11746618" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11746618</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.danek.1994.117">Danek A, Uttner I, Vogl T, Tatsch K, Witt TN. Cerebral involvement in McLeod syndrome. <span><span class="ref-journal">Neurology. </span>1994;<span class="ref-vol">44</span>:117–20.</span> [<a href="/pubmed/8290045" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8290045</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.de_franceschi.2005.1454">De Franceschi L, Rivera A, Fleming M, Honczarenko M, Peters L, Gascard P, Mohandas N, Brugnara C. Evidence for a protective role of the Gardos channel against hemolysis in murine spherocytosis. <span><span class="ref-journal">Blood. </span>2005;<span class="ref-vol">106</span>:1454–9.</span> [<a href="/pmc/articles/PMC1895196/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1895196</span></a>] [<a href="/pubmed/15855279" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15855279</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.dotti.2000.1282">Dotti MT, Battisti C, Malandrini A, Federico A, Rubio JP, Circiarello G, Monaco AP. McLeod syndrome and neuroacanthocytosis with a novel mutation in the XK gene. <span><span class="ref-journal">Mov Disord. </span>2000;<span class="ref-vol">15</span>:1282–4.</span> [<a href="/pubmed/11104227" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11104227</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.dotti.2004">Dotti MT, Malandrini A, Federico A. Neuromuscular findings in eight Italian families with neuroacanthocytosis. In: Danek A, ed. <em>Neuroacanthocytosis Syndromes</em>. Dordrecht, Netherlands: Springer; 2004:127-38.</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.dydak.2006.17">Dydak U, Mueller S, Sandor PS, Meier D, Boesiger P, Jung HH. Cerebral metabolic alterations in McLeod syndrome. <span><span class="ref-journal">Eur Neurol. </span>2006;<span class="ref-vol">56</span>:17–23.</span> [<a href="/pubmed/16914926" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16914926</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.el_nemer.2000.29">El Nemer W, Colin Y, Collec E, Gane P, Cartron JP, Kim CL. Analysis of deletions in three McLeod patients: exclusion of the XS locus from the Xp21.1-Xp21.2 region. <span><span class="ref-journal">Eur J Immunogenet. </span>2000;<span class="ref-vol">27</span>:29–33.</span> [<a href="/pubmed/10651848" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10651848</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.frey.2015.277">Frey BM, Gassner C, Jung HH. Neurodegeneration in the elderly - When the blood type matters: An overview of the McLeod syndrome with focus on hematological features. <span><span class="ref-journal">Transfus Apher Sci. </span>2015;<span class="ref-vol">52</span>:277–84.</span> [<a href="/pubmed/25934153" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25934153</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.gantenbein.2011.2123">Gantenbein AR, Damon-Perri&#x000e8;re N, Bohlender JE, Chauveau M, Latxague C, Miranda M, Jung HH., Tison F. Feeding dystonia in McLeod syndrome. <span><span class="ref-journal">Mov Disord. </span>2011;<span class="ref-vol">26</span>:2123–6.</span> [<a href="/pubmed/21714011" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21714011</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.gassner.2017.2125">Gassner C, Br&#x000f6;nnimann C, Merki Y, Mattle-Greminger MP, Sigurdardottir S, Meyer E, Engstr&#x000f6;m C, O'Sullivan JD, Jung HH, Frey BM. Stepwise partitioning of Xp21: a profiling method for XK deletions causative of the McLeod syndrome. <span><span class="ref-journal">Transfusion. </span>2017;<span class="ref-vol">57</span>:2125–35.</span> [<a href="/pubmed/28555782" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28555782</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.geser.2008">Geser F, Tolnay M, Jung HH. The neuropathology of McLeod syndrome. In: Walker RH, Saiki S, Danek A, eds. <em>Neuroacanthocytosis Syndromes II.</em> Heidelberg, Germany: Springer; 2008:197-203.</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.hardie.1991.13">Hardie RJ, Pullon HW, Harding AE, Owen JS, Pires M, Daniels GL, Imai Y, Misra VP, King RH, Jacobs JM, et al.  Neuroacanthocytosis. A clinical, haematological and pathological study of 19 cases. <span><span class="ref-journal">Brain. </span>1991;<span class="ref-vol">114</span>:13–49.</span> [<a href="/pubmed/1998879" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1998879</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.hewer.2007.3285">Hewer E, Danek A, Schoser BG, Miranda M, Reichard R, Castiglioni C, Oechsner M, Goebel HH, Heppner FL, Jung HH. McLeod myopathy revisited &#x02013; more neurogenic and less benign. <span><span class="ref-journal">Brain. </span>2007;<span class="ref-vol">130</span>:3285–96.</span> [<a href="/pubmed/18055495" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18055495</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.ho.1994.869">Ho M, Chelly J, Carter N, Danek A, Crocker P, Monaco AP. Isolation of the gene for McLeod syndrome that encodes a novel membrane transport protein. <span><span class="ref-journal">Cell. </span>1994;<span class="ref-vol">77</span>:869–80.</span> [<a href="/pubmed/8004674" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8004674</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.ho.1996.672">Ho MF, Chalmers RM, Davis MB, Harding AE, Monaco AP. A novel point mutation in the McLeod syndrome gene in neuroacanthocytosis. <span><span class="ref-journal">Ann Neurol. </span>1996;<span class="ref-vol">39</span>:672–5.</span> [<a href="/pubmed/8619554" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8619554</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.houlden.2003.1423">Houlden H, Lincoln S, Farrer M, Cleland PG, Hardy J, Orrell RW. Compound heterozygous PANK2 mutations confirm HARP and Hallervorden-Spatz syndromes are allelic. <span><span class="ref-journal">Neurology. </span>2003;<span class="ref-vol">61</span>:1423–6.</span> [<a href="/pubmed/14638969" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14638969</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.irvine.2013">Irvine G, Irvine G. An ultra-rare disease? Where do we go from here? <span><span class="ref-journal">Tremor Other Hyperkinet Mov (N Y). </span>2013.</span> Epub ahead of print. [<a href="/pmc/articles/PMC3822404/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3822404</span></a>] [<a href="/pubmed/24255804" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24255804</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.ishikawa.2000.1113">Ishikawa S, Tachibana N, Tabata KI, Fujimori N, Hayashi RI, Takahashi J, Ikeda SI, Hanyu N. Muscle CT scan findings in McLeod syndrome and chorea-acanthocytosis. <span><span class="ref-journal">Muscle Nerve. </span>2000;<span class="ref-vol">23</span>:1113–6.</span> [<a href="/pubmed/10883007" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10883007</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.jung.2007.112">Jung HH, Danek A, Frey BM. McLeod Syndrome &#x02013; a neurohaematological disorder. <span><span class="ref-journal">Vox Sang. </span>2007;<span class="ref-vol">93</span>:112–21.</span> [<a href="/pubmed/17683354" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17683354</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.jung.2011.68">Jung HH, Danek A, Walker RH. Neuroacanthocytosis syndromes. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2011;<span class="ref-vol">6</span>:68.</span> [<a href="/pmc/articles/PMC3212896/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3212896</span></a>] [<a href="/pubmed/22027213" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22027213</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.jung.2004.722">Jung HH, Haker H. Schizophrenia as a manifestation of X-linked Mcleod-Neuroacanthocytosis syndrome. <span><span class="ref-journal">J Clin Psychiatry. </span>2004;<span class="ref-vol">65</span>:722–3.</span> [<a href="/pubmed/15163264" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15163264</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.jung.2001a.384">Jung HH, Hergersberg M, Kneifel S, Alkadhi H, Schiess R, Weigell-Weber M, Daniels G, Kollias S, Hess K. McLeod syndrome: a novel mutation, predominant psychiatric manifestations, and distinct striatal imaging findings. <span><span class="ref-journal">Ann Neurol. </span>2001a;<span class="ref-vol">49</span>:384–92.</span> [<a href="/pubmed/11261514" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11261514</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.jung.2003.928">Jung HH, Hergersberg M, Vogt M, Pahnke J, Treyer V, Rothlisberger B, Kollias SS, Russo D, Frey BM. McLeod phenotype associated with a XK missense mutation without hematologic, neuromuscular, or cerebral involvement. <span><span class="ref-journal">Transfusion. </span>2003;<span class="ref-vol">43</span>:928–38.</span> [<a href="/pubmed/12823753" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12823753</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.jung.2001b.1346">Jung HH, Russo D, Redman C, Brandner S. Kell and XK immunohistochemistry in McLeod myopathy. <span><span class="ref-journal">Muscle Nerve. </span>2001b;<span class="ref-vol">24</span>:1346–51.</span> [<a href="/pubmed/11562915" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11562915</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.kane.1995">Kane J, Havel RJ. Disorder of the biogenesis and secretion of lipoprotein containing the B apolipoproteins. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. <em>The Metabolic and Molecular Bases of Inherited Disease</em>. New York, NY: McGraw-Hill; 1995:1853-85.</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.kassubek.2017.151">Kassubek R, Uttner I, Sch&#x000f6;nfeldt-Lecuona C, Kassubek J, Connemann BJ. Extending the aceruloplasminemia phenotype: NBIA on imaging and acanthocytosis, yet only minor neurological findings. <span><span class="ref-journal">J Neurol Sci. </span>2017;<span class="ref-vol">376</span>:151–2.</span> [<a href="/pubmed/28431603" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28431603</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.kawakami.1999.36">Kawakami T, Takiyama Y, Sakoe K, Ogawa T, Yoshioka T, Nishizawa M, Reid ME, Kobayashi O, Nonaka I, Nakano I. A case of McLeod syndrome with unusually severe myopathy. <span><span class="ref-journal">J Neurol Sci. </span>1999;<span class="ref-vol">166</span>:36–9.</span> [<a href="/pubmed/10465497" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10465497</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.laurencin.2018.64">Laurencin C, Sebbag L, Jousserand G, Demontes M, Campean L, Thivolet-Bejui F, Lebre AS, Thobois S. Novel XK mutation in a McLeod patient diagnosed after heart transplant. <span><span class="ref-journal">Clin Neurol Neurosurg. </span>2018 May;<span class="ref-vol">168</span>:64–66.</span> [<a href="/pubmed/29524658" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29524658</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.lee.2000.93">Lee S, Russo D, Redman C. Functional and structural aspects of the Kell blood group system. <span><span class="ref-journal">Transfus Med Rev. </span>2000;<span class="ref-vol">14</span>:93–103.</span> [<a href="/pubmed/10782495" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10782495</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.lee.2007.365">Lee S, Sha Q, Wu X, Calenda G, Peng J. Expression profiles of mouse Kell, XK, and XPLAC mRNA. <span><span class="ref-journal">J Histochem Cytochem. </span>2007;<span class="ref-vol">55</span>:365–74.</span> [<a href="/pubmed/17189525" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17189525</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.lux.2016.187">Lux SE 4th. Anatomy of the red cell membrane skeleton: unanswered questions. <span><span class="ref-journal">Blood. </span>2016;<span class="ref-vol">127</span>:187–99.</span> [<a href="/pubmed/26537302" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26537302</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.mohiddin.2004">Mohiddin SA, Fananapazzir L. Cardiac involvement in the neuroacanthocytosis syndromes. In: Danek A, ed. <em>Neuroacanthocytosis Syndromes</em>. Dordrecht, Netherlands: Springer; 2004:139-52.</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.nicholl.2004.1200">Nicholl DJ, Sutton I, Dotti MT, Supple SG, Danek A, Lawden M. White matter abnormalities on MRI in neuroacanthocytosis. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2004;<span class="ref-vol">75</span>:1200–1.</span> [<a href="/pmc/articles/PMC1739157/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1739157</span></a>] [<a href="/pubmed/15258233" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15258233</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.oechslin.2009.130">Oechslin E, Kaup D, Jenni R, Jung HH. Cardiac abnormalities in McLeod syndrome. <span><span class="ref-journal">Int J Cardiol. </span>2009;<span class="ref-vol">132</span>:130–2.</span> [<a href="/pubmed/18045706" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18045706</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.oechsner.2001.517">Oechsner M, Buchert R, Beyer W, Danek A. Reduction of striatal glucose metabolism in McLeod choreoacanthocytosis. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2001;<span class="ref-vol">70</span>:517–20.</span> [<a href="/pmc/articles/PMC1737311/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1737311</span></a>] [<a href="/pubmed/11254778" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11254778</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF._yen.1996.160">&#x000d8;yen R, Reid ME, Rubinstein P, Ralph H. A method to detect McLeod phenotype red blood cells. <span><span class="ref-journal">Immunohematology. </span>1996;<span class="ref-vol">12</span>:160–3.</span> [<a href="/pubmed/15387728" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15387728</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.peng.2007.142">Peng J, Redman CM, Wu X, Song X, Walker RH, Westhoff CM, Lee S. Insights into extensive deletions around the XK locus associated with McLeod phenotype and characterization of two novel cases. <span><span class="ref-journal">Gene. </span>2007;<span class="ref-vol">392</span>:142–50.</span> [<a href="/pmc/articles/PMC1931494/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1931494</span></a>] [<a href="/pubmed/17300882" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17300882</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.rivera.2013.80">Rivera A, Kam S, Ho M, Romero J, Lee S. Ablation of the Kell/Xk complex alters erythrocyte divalent cation homeostasis. <span><span class="ref-journal">Blood Cells Mol Dis. </span>2013;<span class="ref-vol">50</span>:80–5.</span> [<a href="/pmc/articles/PMC3540154/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3540154</span></a>] [<a href="/pubmed/23122227" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23122227</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.roulis.2018.1554">Roulis E, Hyland C, Flower R, Gassner C, Jung HH, Frey BM. <span><span class="ref-journal">JAMA Neurol. </span>2018;<span class="ref-vol">75</span>:1554–62.</span> [<a href="/pubmed/30128557" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30128557</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.russo.1998.13950">Russo D, Redman C, Lee S. Association of XK and Kell blood group proteins. <span><span class="ref-journal">J Biol Chem. </span>1998;<span class="ref-vol">273</span>:13950–6.</span> [<a href="/pubmed/9593744" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9593744</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.russo.2000.340">Russo D, Wu X, Redman CM, Lee S. Expression of Kell blood group protein in nonerythroid tissues. <span><span class="ref-journal">Blood. </span>2000;<span class="ref-vol">96</span>:340–6.</span> [<a href="/pubmed/10891471" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10891471</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.singleton.2003.682">Singleton BK, Green CA, Renaud S, Fuhr P, Poole J, Daniels GL. McLeod syndrome resulting from a novel XK mutation. <span><span class="ref-journal">Br J Haematol. </span>2003;<span class="ref-vol">122</span>:682–5.</span> [<a href="/pubmed/12899725" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12899725</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.storch.2005.84">Storch A, Kornhass M, Schwarz J. Testing for acanthocytosis A prospective reader-blinded study in movement disorder patients. <span><span class="ref-journal">J Neurol. </span>2005;<span class="ref-vol">252</span>:84–90.</span> [<a href="/pubmed/15654559" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15654559</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.supple.2001.369">Supple SG, Iland HJ, Barnett MH, Pollard JD. A spontaneous novel XK gene mutation in a patient with McLeod syndrome. <span><span class="ref-journal">Br J Haematol. </span>2001;<span class="ref-vol">115</span>:369–72.</span> [<a href="/pubmed/11703337" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11703337</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.sveinsson.2018">Sveinsson O, Udd B, Svenningsson P, Gassner C, Engstr&#x000f6;m C, Laffita-Mesa JM, Solders G, Herteg&#x000e5;rd S, Savitcheva I, Jung HH, Tolnay M, Frey BM, Paucar M. Novel Xp21.1 deletion associated with unusual features in a large McLeod syndrome kindred. <span><span class="ref-journal">Parkinsonism Relat Disord. </span>2018.</span> Epub ahead of print.</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.swash.1983.717">Swash M, Schwartz MS, Carter ND, Heath R, Leak M, Rogers KL. Benign X-linked myopathy with acanthocytes (McLeod syndrome). Its relationship to X-linked muscular dystrophy. <span><span class="ref-journal">Brain. </span>1983;<span class="ref-vol">106</span>:717–33.</span> [<a href="/pubmed/6685553" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6685553</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.symmans.1979.575">Symmans WA, Shepherd CS, Marsh WL, &#x000d8;yen R, Shohet SB, Linehan BJ. Hereditary acanthocytosis associated with the McLeod phenotype of the Kell blood group system. <span><span class="ref-journal">Br J Haematol. </span>1979;<span class="ref-vol">42</span>:575–83.</span> [<a href="/pubmed/476009" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 476009</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.tarugi.2011.81">Tarugi P, Averna M. Hypobetalipoproteinemia: genetics, biochemistry, and clinical spectrum. <span><span class="ref-journal">Adv Clin Chem. </span>2011;<span class="ref-vol">54</span>:81–107.</span> [<a href="/pubmed/21874758" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21874758</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.valko.2010.612">Valko PO, H&#x000e4;nggi J, Meyer M, Jung HH. Evolution of striatal degeneration in McLeod syndrome. <span><span class="ref-journal">Eur J Neurol. </span>2010;<span class="ref-vol">17</span>:612–8.</span> [<a href="/pubmed/19968700" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19968700</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.walker.2007a.299">Walker RH, Danek A, Uttner I, Offner R, Reid M, Lee S. McLeod phenotype without the McLeod syndrome. <span><span class="ref-journal">Transfusion. </span>2007a;<span class="ref-vol">47</span>:299–305.</span> [<a href="/pubmed/17302777" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17302777</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.walker.2007b.244">Walker RH, Jung HH, Tison F, Lee S, Danek A. Phenotypic variation among brothers with the McLeod neuroacanthocytosis syndrome. <span><span class="ref-journal">Mov Disord. </span>2007b;<span class="ref-vol">22</span>:244–8.</span> [<a href="/pubmed/17133513" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17133513</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.walker.2019.158">Walker RH, Miranda M, Jung HH, Danek A. Life expectancy and mortality in chorea-acanthocytosis and McLeod syndrome. <span><span class="ref-journal">Parkinsonism Relat Disord. </span>2019;<span class="ref-vol">60</span>:158–61.</span> [<a href="/pubmed/30245172" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30245172</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.walterfang.2011.1275">Walterfang M, Evans A, Looi JC, Jung HH, Danek A, Walker RH, Velakoulis D. The neuropsychiatry of neuroacanthocytosis syndromes. <span><span class="ref-journal">Neurosci Biobehav Rev. </span>2011;<span class="ref-vol">35</span>:1275–83.</span> [<a href="/pubmed/21237198" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21237198</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.wendel.2004.1579">Wendel S, Font&#x000e3;o-Wendel R, Levi JE, Aravechia MG, Bordokan RF, Russo D, Haddad MS. A. McLeod phenotype detected by random screening for K:-4 [Kp(b-)] blood donors in Brazil. <span><span class="ref-journal">Transfusion. </span>2004;<span class="ref-vol">44</span>:1579–87.</span> [<a href="/pubmed/15504163" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15504163</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mcleod.REF.witt.1992.302">Witt TN, Danek A, Reiter M, Heim MU, Dirschinger J, Olsen EG. McLeod syndrome: a distinct form of neuroacanthocytosis. Report of two cases and literature review with emphasis on neuromuscular manifestations. <span><span class="ref-journal">J Neurol. </span>1992;<span class="ref-vol">239</span>:302–6.</span> [<a href="/pubmed/1512605" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1512605</span></a>]</div></li></ul></div></div><div id="mcleod.Chapter_Notes"><h2 id="_mcleod_Chapter_Notes_">Chapter Notes</h2><div id="mcleod.Author_Notes"><h3>Author Notes</h3><p>Hans H Jung is a leading senior consultant at the Department of Neurology, University Hospital Zurich, Switzerland where he is head of the Center for Neurogenetic and Neuromuscular Disorders. His research focuses on the clinical, pathologic, and molecular basis of chorea syndromes, in particular the McLeod neuroacanthocytosis syndrome.</p><p>Adrian Danek, a professor of cognitive neurology at the University of Munich, has contributed to neuroacanthocytosis research since 1990. His interests also include functional brain anatomy, problem solving (Towers of Hanoi/London), the frontotemporal lobe degeneration syndromes (see <a href="http://www.ftld.de" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ftld.de</a>), and other <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> dementias.</p><p>Ruth H Walker is a movement disorders-trained neurologist whose research focuses on the functional neuroanatomy of the basal ganglia and clinicopathologic correlations of neurogenetic disorders. Her particular clinical interests are the hyperkinetic disorders, especially the rarer inherited causes of chorea.</p><p>Beat M Frey is a board certified hematologist/oncologist/transfusion specialist running the Swiss Transfusion Service SRC in Schlieren/Z&#x000fc;rich, Switzerland. His research interests focus on functional and genetic aspects of blood group antigens and their implication for clinical practice.</p><p>Christoph Gassner specializes in molecular blood group <a class="def" href="/books/n/gene/glossary/def-item/genotyping/">genotyping</a>. In the context of McLeod, his research has primarily focused on establishing reliable genetic methods for the detection of pathogenic variants in <i>XK</i> and large X-chromosomale deletions. He has published on <i>KEL</i> genetics, with special focus on <i>KEL</i> <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> and other variants and currently acts as co-chair together with Catherine Hyland (Australian Red Cross Blood Service, Kelvin Grove, Queensland, Australia) of the ISBT Working Party Red Cell Immunogenetics and Blood Group Terminology.</p></div><div id="mcleod.Acknowledgments"><h3>Acknowledgments</h3><p>The authors thank The Advocacy for Neuroacanthocytosis Patients, in particular the late Glenn Irvine and his wife Ginger, for their continuous and ongoing support.</p></div><div id="mcleod.Author_History"><h3>Author History</h3><p>Adrian Danek, MD (2004-present) <br />Carol Dobson-Stone, DPhil; University of New South Wales (2004-2012) <br />Beat M Frey, MD (2012-present)<br />Christoph Gassner, PhD (2012-present)<br />Hans H Jung, MD (2004-present) <br />Sohee Lee, PhD; New York Blood Center (2007-2012) <br />Colvin M Redman, PhD; New York Blood Center (2004-2007) <br />Ruth H Walker, MD, MBBS, PhD (2012-present)</p></div><div id="mcleod.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>23 May 2019 (bp) Comprehensive update posted live</div></li><li class="half_rhythm"><div>17 May 2012 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>26 March 2007 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>3 December 2004 (ca) Review posted live</div></li><li class="half_rhythm"><div>8 April 2004 (hj, ad) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1354</span><span class="label">PMID: <a href="/pubmed/20301528" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301528</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/mkks/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/mcad/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1354&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1354/?report=reader">PubReader</a></li><li><a href="/books/NBK1354/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1354" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1354" style="display:none" title="Cite this Page"><div class="bk_tt">Jung HH, Danek A, Walker RH, et al. McLeod Neuroacanthocytosis Syndrome. 2004 Dec 3 [Updated 2019 May 23]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1354/pdf/Bookshelf_NBK1354.pdf">PDF version of this page</a> (520K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#mcleod.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#mcleod.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#mcleod.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#mcleod.Genetically_Related_Allelic_Disor" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#mcleod.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#mcleod.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#mcleod.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#mcleod.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#mcleod.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#mcleod.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#mcleod.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=7504[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">XK</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1468528" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1468528" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1468528" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1468528" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301604" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">NR0B1-</i>Related Adrenal Hypoplasia Congenita</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">NR0B1-</i>Related Adrenal Hypoplasia Congenita<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Achermann JC, Vilain EJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24006547" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lichter-Konecki U, Caldovic L, Morizono H, Simpson K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301298" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Dystrophinopathies</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Dystrophinopathies<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Darras BT, Urion DK, Ghosh PS. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25299040" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Barth Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Barth Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Ferreira C, Thompson R, Vernon H. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301503" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Disorders of Intracellular Cobalamin Metabolism</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Disorders of Intracellular Cobalamin Metabolism<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sloan JL, Carrillo N, Adams D, Venditti CP. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301528" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301528" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e04193adde089116947b0bd">McLeod Neuroacanthocytosis Syndrome - GeneReviews®</a><div class="ralinkpop offscreen_noflow">McLeod Neuroacanthocytosis Syndrome - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:21:46-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal106&amp;ncbi_phid=CE8D2CC9E03FE721000000000B0003B6&amp;ncbi_session=CE8D2CC9E0419391_2816SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1354%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1354&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1354/&amp;ncbi_pagename=McLeod Neuroacanthocytosis Syndrome - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8D2CC9E0419391_2816SID /projects/books/PBooks@5.22 portal106 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>